TWI308912B - Process for preparing 2-oxo-1-pyrrolidine derivatives - Google Patents
Process for preparing 2-oxo-1-pyrrolidine derivatives Download PDFInfo
- Publication number
- TWI308912B TWI308912B TW90107984A TW90107984A TWI308912B TW I308912 B TWI308912 B TW I308912B TW 90107984 A TW90107984 A TW 90107984A TW 90107984 A TW90107984 A TW 90107984A TW I308912 B TWI308912 B TW I308912B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- formula
- alkyl
- hydrogen
- compound
- Prior art date
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
1308912 五、發明説明(1 ) 本發明係有關2-氧基-1 -吡咯啶衍生物及其製法及其用 途。本發明亦係關於由未飽和2-氧基-1-吡咯啶衍生物製 備α -乙基-2-氧基-卜吡咯啶乙醯胺衍生物之方法。 特別本發明係有關新穎中間物及其用於製備(S)-(-)- α -乙基-2_氧基-1-吡咯啶乙醯胺之方法,其於國際非專屬名 稱命名爲左堤拉西坦(Levetiracetam)、其右旋對映異構物 及相關化合物。左堤拉西坦顯示爲具有如下結構式··1308912 V. INSTRUCTION DESCRIPTION OF THE INVENTION (1) The present invention relates to a 2-oxy-1 -pyrrolidine derivative, a process for the preparation thereof and use thereof. The present invention is also directed to a process for preparing an α-ethyl-2-oxy-pyrrolidinium derivative from an unsaturated 2-oxy-1-pyrrolidine derivative. In particular, the present invention relates to novel intermediates and methods for preparing (S)-(-)-α-ethyl-2-oxy-1-pyrrolidinium, which are named after the international non-exclusive name. Levetiracetam, its dextrorotatory enantiomer and related compounds. Levetiracetam is shown to have the following structural formula··
左堤拉西坦 左堤拉西坦爲一種左旋化合物,於歐洲專利案第1 62036 號揭示作爲中樞神經系統之缺氧及缺血型發作的治療及預 防。此種化合物也可用於治療癲癇,癲癇爲一種治療適應 症而已經驗證本發明之右旋對映異構物(R)-( + )_ α -乙基-2-氧基-1-吡咯啶乙醯胺完全缺乏活性(A.】. GOWER等人’ 歐洲藥理期刊,222,( 1 992),1 93-203)。最後,歐洲專利 申請案第〇 64 5 1 3 9號顯示此種化合物具有解除焦慮活性。 非對稱碳原子帶有一個位在紙張平面上的氫原子(圖中未顯示) 。左堤拉西坦之製備述於歐洲專利案第〇 162 036號以及英國專 利案第2 225 322號,二案皆讓與本發明之受讓人。右旋對映異 構物(R)-(+)- α -乙基-2-氧基-1 -吡咯啶乙醯胺之製備揭示於歐洲 專利案第〇 165 919號。雖言如此,此等辦法無法全然滿足 1308912 A7 五 、發明說明(2) 工業製程的需求。因此,透過新穎前驅物之非對稱氫化反 應開發新辦法。 於一特徵方面,本發明提供一種具有通式(A)化合物及 其醫藥可接受性鹽之化合物。Levetiracetam Levetiracetam is a levorotatory compound disclosed in European Patent No. 1 62036 as a treatment and prevention of hypoxia and ischemic episodes of the central nervous system. Such compounds are also useful in the treatment of epilepsy, which has been tested for the right-handed enantiomer (R)-(+)_α-ethyl-2-oxy-1-pyrrolidine of the present invention as a therapeutic indication. Acetamide is completely inactive (A.). GOWER et al., European Journal of Pharmacology, 222, (1 992), 1 93-203). Finally, European Patent Application No. 64 5 1 3 9 shows that such compounds have an anxiolytic activity. An asymmetric carbon atom carries a hydrogen atom on the plane of the paper (not shown). The preparation of levetiracetam is described in the European Patent No. 162 036 and the British Patent No. 2 225 322, both of which are assigned to the assignee of the present invention. The preparation of the dextrorotatory enantiomer (R)-(+)-α-ethyl-2-oxo-1-pyrrolidineacetamide is disclosed in European Patent No. 165 919. Having said that, these methods cannot fully meet the requirements of 1308912 A7 V. Inventions (2) Industrial processes. Therefore, new approaches have been developed through asymmetric hydrogenation reactions of novel precursors. In a characteristic aspect, the present invention provides a compound having a compound of the formula (A) and a pharmaceutically acceptable salt thereof.
Ο (A) (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 其中,X 爲-CONR5R6 或-COOR7 或-CO-R8 或 CN ; R1爲氫或烷基,芳基,雜環烷基,雜芳基,鹵原子, 經基’胺基,硝基,氰基; R2 ' R3、R4爲相同或相異,且各自分別爲氫或鹵原子 ,羥基,胺基,硝基,氰基,醯基,醯氧基,磺醯基,亞 磺醯基’烷基胺基,羧基,酯基,醚基,醯胺基,磺酸基 ’磺醯胺基,烷基磺醯基,芳基磺醯基,烷氧羰基、烷基 亞磺醯基、芳基亞磺醯基,烷硫基,芳硫基,烷基,烷氧 基,氧酯基,氧醯胺基,芳基,芳基胺基,芳氧基,雜環 烷基,雜芳基,乙烯基; R5、R6、R7爲相同或相異,且各自分別爲氫,羥基, 烷基,芳基,雜環烷基,雜芳基,烷氧基,芳氧基;以及 R8爲氫,經基,疏基,鹵原子’院基,芳基,雜環院 基,雜芳基,烷硫基,芳硫基。 院基一詞用於此處包括具有直鏈' 分支或環狀部分或其 -4- 本纸張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 裳-----訂 ----I--- 1308912 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明() 組合且含有1-20個碳原子及較佳1-5個碳原子之飽和一價 烴基。烷基可選擇性經以1至5個分別選自鹵原子、羥基 、巯基、胺基、硝基、氰基、醯基、醯氧基、磺醯基、亞 磺醯基、烷基胺基、羧基、酯基、醚基、醯胺基、磺酸基 、磺醯胺基、烷基磺醯基、芳基磺醯基、烷氧羰基、烷基 亞磺醯基、芳基亞磺醯基、烷硫基、芳硫基、氧酯基、氧 醯胺基、雜環烷基、雜芳基、乙烯基、(Ci-Cs)烷氧基、 (C6-Cic)芳氧基、(C6-Ci())芳基組成的組群之取代基取代。 較佳烷基爲甲基、乙基、丙基、異丙基、丁基、異-或第 三-丁基、2,2,2-三甲基乙基或經以至少一個選自鹵原子、 羥基、巯基、胺基、硝基、氰基組成的組群之基取代,例 如三氟甲基,三氯甲基,2,2,2-三氯乙基,1,1-二甲基-2,2-二溴乙基,1,1-二甲基-2,2,2-三氯乙基。 「雜環烷基」一詞用於此處表示如前定義之「(G-C6)環 烷基」,帶有至少一個〇、S及/或N原子岔斷碳環系環結 構例如四氫呋喃基,四氫吡喃基,六氫吡啶基,六氫吡畊 基,嗎啉基,吡咯啶基或經以至少一個選自鹵原子、羥基 、锍基、胺基、硝基、氰基組成的組群之基取代。 「烷氧基」一詞用於此處包括-0-烷基,其中「烷基」 定義如前。較佳烷基爲甲基、乙基、丙基、異丙基、丁基 、異-或第三-丁基、2,2,2-三甲基乙基或經以至少一個鹵基 取代之基,例如三氟甲基,三氯甲基,2,2,2-三氯乙基, M-二甲基-2,2-二溴乙基,1,1-二甲基-2,2,2·三氯乙基。 「烷硫基」一詞用於此處包括-S-烷基,其中「烷基」 (請先閱讀背面之注音?事項再填寫本頁) ,裝 ----訂— t 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 A7 B7 五、發明說明() , 定義如前。較佳烷基爲甲基、乙基、丙基、異丙基、丁基 、異-或第三-丁基' 2,2,2-三甲基乙基或經以至少一個鹵基 取代之基’例如三氟甲基,三氯甲基,2,2,2-三氯乙基, 1,卜二甲基-2,2-二溴乙基,1,1-二甲基-2,2,2-三氯乙基。 「院基胺基」一詞用於此處包括-NH院基或-N(院基)2 基’其中「烷基」定義如前。較佳烷基爲甲基、乙基、丙 基、正丙基、異丙基、丁基、異-或第三-丁基、2,2,2-三甲 基乙基或經以至少一個鹵基取代之基。 「芳基」一詞用於此處包括經由去除一個氫原子而衍生 自芳族烴之有機基團,例如苯基,苯氧基,萘基,芳烷基 ’苄基,選擇性經以1至5個分別選自鹵原子、羥基、锍 基、胺基、硝基、氰基、醯基、醯氧基、磺醯基、亞磺醯 基、烷基胺基、羧基、酯基、醚基、醯胺基、磺酸基、磺 醯胺基、烷基磺醯基、烷氧羰基、烷基亞磺醯基、烷硫基 、氧酯基、氧醯胺基、芳基、(CVC6)烷氧基、(c6-c1Q)芳 氧基及(C6-C1Q)芳基組成的組群之取代基取代。芳基係由 1-3個環組成,較佳由1個環組成,且含有2-30個碳原子 且較佳爲6-10個碳原子。較佳芳基爲苯基、幽苯基、氰 基苯基、硝基苯基、甲氧苯基、萘基、苄基'鹵苄基、氰 基苄基、甲氧苄基、硝基苄基、2-苯基乙基。 「芳基胺基」一詞用於此處包括-NH芳基或-N(芳基)2 基,其中「芳基」定義如前。較佳芳基爲苯基、鹵苯基、 氰基苯基、硝基苯基、甲氧苯基、萘基、鹵苄基、氰基苄 基、甲氧苄基、硝基苄基、2_苯基乙基。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝 *· ^1 ^1 ·_1·-fn n n n _ 經濟部智慧財產局員工消費合作社印製 1308912 ^____ 經濟部智慧財產局員工消費合作社印製 A7 B7 發明說明() 「'芳氧基」一詞用於此處包括-0 -芳基,其中「芳基」 定義如前。較佳芳基爲苯基、鹵苯基、氰基苯基、硝基苯 基、甲氧苯基、苄基、鹵苄基、氰基苄基、甲氧;基、硝 基苄基、2-苯基乙基。 「芳硫基」一詞用於此處包括-S-芳基,其中「芳基」 定義如前。較佳芳基爲苯基、鹵苯基、氰基苯基、硝基苯 基、甲氧苯基、苄基、鹵苄基、氰基苄基、甲氧;基、硝 基苄基、2-苯基乙基。 「鹵原子」一詞用於此處包括Cl、Br、F、I原子。 「羥基」一詞用於此處表示式-0H基。 「锍基」一詞用於此處表示式-SH基。 「氰基」一詞用於此處表示式-CN基。 「硝基」一詞用於此處表示式-N〇2基。 「胺基」一詞用於此處表示式·ΝΗ2基。 「羧基」一詞用於此處表示式-C00H基。 「磺酸基」一詞用於此處表示式-S03H基。 「磺醯胺基」一詞用於此處表示式-so2nh2基。 「雜芳基」一詞用於此處除另行指示,否則表示如前定義 之「芳基」帶有至少一個〇、s及/或N岔斷碳環系環結構 ,例如壯π定基,呋喃基,吡略基,噻吩基,異塵Π坐基,咪 唑基,苯并咪唑基,四唑基,吡畊基,嘧啶基,喹啉基, 異喹啉基,異苯并呋喃基’苯并噻吩基,吡唑基,吲哚基 ,異吲哚基,嘌呤基,卡巴唑基,異噚唑基,噻唑基,曙 唑基,苯并噻唑基,或苯并噚唑基,選擇性經以至5個分 -7- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐〉 —i—I —裝—!—訂--------- (請先閱讀背面之注意事項再填寫本頁) 1308912 A7 __B7___ 五、發明說明(6 ) (請先閱讀背面之注意事項再填寫本頁) 別選自羥基、鹵原子、毓基、胺基、硝基、氰基、醯基、 醯氧基、磺醯基、亞磺醯基、烷基胺基、羧基、酯基、醚 基、醯胺基、磺酸基、磺醯胺基、烷基磺醯基、烷氧羰基 、氧酯基、氧醯胺基、烷氧羰基、(Q-Cs)烷氧基、及 (c^c5)烷基組成的組群之取代基取代。 「芳烷氧」一詞用於此處表示式芳基-(匕-山烷基)-之基 。較佳芳烷基爲苄基、鹵苄基、氰基苄基、甲氧苄基、硝 基苄基、2-苯乙基、二苯甲基、(4-甲氧苯基)二苯甲基。 「醯基」一詞用於此處表示羧酸基團,如此包括式烷 基-CO-、芳基-CO-、雜芳基-CO-、芳烷基-CO-之基,其中 各個羥基團定義如此節。較佳烷基爲甲基、乙基、丙基、 異丙基、丁基、異-或第三-丁基、2,2,2-三甲基乙基或經以 至少一個鹵基取代之基。較佳芳基爲苯基、幽苯基、氰基 苯基、硝基苯基、甲氧苯基、苄基、鹵苄基、氰基苄基、 甲氧苄基、硝基苄基、2-苯基乙基。 經濟部智慧財產局員工消費合作社印製 「氧醯基」一詞用於此處表示羧酸基團,如此包括式烷 基-C0-0-、芳基-C0-0-、雜芳基-CO-O-、芳烷基-C0-0-之基,其中各個羥基定義如此處。較佳烷基及芳基係如同 對醯基之定義。 「磺醯基」一詞表示式-s〇2-烷基或-so2-芳基之基,其 中「院基」及「方基」定義如前。較佳院基爲甲基、乙基 、丙基、異丙基、丁基、異·或第三-丁基、2,2,2-三甲基乙 基或經以至少一個鹵基取代之基。較佳芳基爲苯基、鹵苯 基、氰基苯基、硝基苯基、甲氧苯基、苄基、鹵苄基、氰 -8- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 A7 B7 五 經濟部智慧財產局員工消費合作社印製 發明說明() 基苄基、甲氧苄基、硝基苄基、2-苯基乙基。 「亞擴酿基」一詞表示式-S0 -院基或_s0_芳基之基’其 中「院基」及「芳基」定義如前。較佳院基爲甲基、乙基 、丙基、異丙基、丁基、異-或第三-丁基、2,2,2-三甲基乙 基或經以至少一個鹵基取代之基。較佳芳基爲苯基、鹵苯 基、氰基苯基、硝基苯基、甲氧苯基、;基、鹵;基、氰 基苄基、甲氧苄基、硝基苄基' 2-苯基乙基。 「酯基」一詞表示式- C00 -院基或- C00 -芳基之基’其 中「烷基」及「芳基」定義如前。較佳烷基爲甲基、乙基 、丙基、異丙基、丁基、異-或第三-丁基、2,2,2-三甲基乙 基或經以至少一個鹵基取代之基。較佳芳基爲苯基、鹵苯 基、氰基苯基、硝基苯基、甲氧苯基、亨基、鹵辛基、氰 基苄基、甲氧苄基、硝基苄基、2-苯基乙基。 「氧酯基」一詞表示式-ο-coo-烷基或-0-C00-芳基之 基,其中「烷基」及「芳基」定義如前。較佳烷基爲甲基 、乙基、丙基、異丙基、丁基、異-或第三-丁基、2,2,2-三 甲基乙基或經以至少一個鹵基取代之基。較佳芳基爲苯基 、鹵苯基、氰基苯基、硝基苯基、甲氧苯基、苄基、齒苄 基、氰基苄基、甲氧苄基、硝基苄基、2-苯基乙基。 「醚基」一詞表示式烷基·〇-烷基或烷基-0-芳基或芳基-〇-芳基之基,其中「烷基」及「芳基」定義如前。較佳烷 基爲甲基、乙基、丙基、異丙基、丁基、異-或第三·丁基 、2,2,2-三甲基乙基或經以至少一個鹵基取代之基。較佳 芳基爲苯基、鹵苯基、氰基苯基、硝基苯基、甲氧苯基、 -9- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公复) .—*—裝--------訂---------AWI (請先閱讀背面之注咅?事項再填寫本頁) 氧醯胺基 經濟部智慧財產局員工消費合作社印製 1308912 A7 B7 五、發明說明() 苄基、鹵苄基、氰基苄基、甲氧苄基、硝基苄基、2-苯基 乙基。 「醯胺基」一詞表示式_C0NH2_或-C0NH院基或_C0N (烷基)2或-CHNH芳基或_C〇N(方基)2之基,其中「烷基」 及「芳基」定義如前。較佳烷基含1-4個碳原子,及芳基 含6-10個碳原子。較佳院基爲甲基 '乙基、丙基、異丙 基、丁基、異-或第三-丁基、2,2,2-三甲基乙基或經以至少 一個鹵基取代之基。較佳芳基爲苯基' 鹵苯基、氰基苯基 、硝基苯基、甲氧苯基、苄基、鹵苄基、氰基苄基、甲氧 苄基、硝基苄基、2-苯基乙基。 詞表示式-0-CONH2-或-0-C0NH烷基 或-0-C0N(烷基)2或-〇-C〇NH芳基或-0-C0N(芳基)2之基 ,其中「院基」及「芳基」定義如前。較佳烷基含1 - 5個 碳原子及芳基含6-8個碳原子。較佳烷基爲甲基、乙基、 丙基、異丙基、丁基、異-或第三-丁基、2,2,2-三甲基乙基 或經以至少一個鹵基取代之基。較佳芳基爲苯基、鹵苯基 、氰基苯基、硝基苯基、甲氧苯基、苄基、鹵苄基、氰基 午基、甲氧辛基、硝基韦基、2 -苯基乙基。 較佳R1爲甲基,乙基,丙基,異丙基,丁基,異-或第 三-丁基,2,2,2-三甲基乙基或經以至少一個鹵基取代之基 ,例如三氟甲基,三氯甲基,2,2,2-三氯乙基,1,1-二甲 基-2,2-二溴乙基,1,1-二甲基-2,2,2-三氯乙基。 較佳R2、R3及R4分別爲氫或鹵原子或甲基,乙基,丙 基’異丙基,丁基,異-或第三·丁基,2,2,2-三甲基乙基或 .10. 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) I.裝 1308912 Α7 Β7 五、發明說明() 經以至少一個鹵基取代之基,例如三氟甲基,三氯甲基, 2.2.2- 三氯乙基,1,1-二甲基-2,2-二溴乙基,1,1-二甲基- (請先閱讀背面之注意事項再填寫本頁) 2.2.2- 三氯乙基。 較佳R5及R6爲甲基,乙基,丙基,異丙基,丁基,異-或第三-丁基,2,2,2-三甲基乙基。 較佳R7爲氫,甲基,乙基,丙基,異丙基,丁基,異-或第三-丁基,2,2,2-三甲基乙基,甲氧基,乙氧基,苯基 ,苄基,或經以至少一個鹵基取代之基例如三氟甲基,氯 苯基。 較佳R8爲氫,甲基,乙基,丙基,異丙基,丁基,異-或第三-丁基,2,2,2-三甲基乙基,苯基,苄基,或經以至 少一個鹵基取代之基例如三氟甲基,氯苄基或此處X爲-CN。 除非另行陳述,否則此處述及通式(A)化合物無論個別 表示或集合表示意圖包括幾何異構物亦即Z(住沙門 (Zusanimen))及E(安久占(Entgegen))異構物及其混合物 (外消旋混合物)。 經濟部智慧財產局員工消費合作社印製 就後述非對稱氫化方法而言,對式(A)化合物之Z(住沙 門)及E(安久占)異構物(其中R1爲甲基,R2及R4爲Η及 X爲-CONH2或-COOME或-COOEt或-COOH)獲得最佳結果 。於此組群,以其中R3爲.氫,.烷基纟提燦基* (特別二氟乙烯基)之化合物特別適宜: ( — ............ . — — —< 本發明之一特徵方面係有關一種製備具有通式(A)化合 物之方法,此種方法包括下列反應: -11- 本纸張尺度適用中國國家標準(εΝέ)Α4規格(210 X 297公釐) 1308912 經濟部智慧財產局員工消費合作社印製 A7 B7 10、 發明說明() 通式(A)化合物此處X爲-CONR5R6或-COOR7或 -CO-R8或CK ’可方便地經由通式(C)之α-酮基羧酸衍生 物此處R1及X定義如前,與通式(D)之吡咯啶酮此處R2、 R3、R4定義如前根據如下反應圖(1)反應製備。Ο (A) (Please read the notes on the back and fill out this page.) Printed by the Intellectual Property Office of the Ministry of Economic Affairs, the consumer consortium, where X is -CONR5R6 or -COOR7 or -CO-R8 or CN; R1 is hydrogen or alkyl , aryl, heterocycloalkyl, heteroaryl, halogen atom, aryl group, nitro group, cyano group; R2 'R3, R4 are the same or different, and each is hydrogen or a halogen atom, a hydroxyl group, Amine, nitro, cyano, decyl, decyloxy, sulfonyl, sulfinyl 'alkylamino, carboxy, ester, ether, decyl, sulfonyl 'sulfonamide , alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, alkylsulfinyl, arylsulfinyl, alkylthio, arylthio, alkyl, alkoxy, oxyester, Oxidantamine, aryl, arylamine, aryloxy, heterocycloalkyl, heteroaryl, vinyl; R5, R6, R7 are the same or different, and each is hydrogen, hydroxy, alkyl , aryl, heterocycloalkyl, heteroaryl, alkoxy, aryloxy; and R8 are hydrogen, thiol, sulfhydryl, halogen atom, aryl, aryl, heterocyclic, heteroaryl, Alkylthio, arylthio . The term "hospital base" is used herein to include a straight-chain 'branched or toroidal part or its -4- paper scale applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 mm). ----I--- 1308912 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau Employees Consumption Cooperatives Printing 5, Inventions () Combined and saturated monovalent hydrocarbon groups containing 1-20 carbon atoms and preferably 1-5 carbon atoms . The alkyl group may be optionally selected from 1 to 5, respectively, selected from a halogen atom, a hydroxyl group, a decyl group, an amine group, a nitro group, a cyano group, a decyl group, a decyloxy group, a sulfonyl group, a sulfinyl group, an alkylamino group. , carboxy, ester, ether, decyl, sulfonate, sulfonylamino, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, alkylsulfinyl, arylsulfin Base, alkylthio, arylthio, oxyester, oxoamine, heterocycloalkyl, heteroaryl, vinyl, (Ci-Cs) alkoxy, (C6-Cic) aryloxy, ( Substituent substitution of the C6-Ci()) aryl group. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or at least one selected from halogen atoms a group of a group consisting of a hydroxyl group, a thiol group, an amine group, a nitro group, and a cyano group, such as a trifluoromethyl group, a trichloromethyl group, a 2,2,2-trichloroethyl group, and a 1,1-dimethyl group. -2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl. The term "heterocycloalkyl" is used herein to mean "(G-C6)cycloalkyl" as defined above, with at least one oxime, S and/or N atom cleavage carbocyclic ring structure such as tetrahydrofuranyl. , tetrahydropyranyl, hexahydropyridyl, hexahydropyridinyl, morpholinyl, pyrrolidinyl or by at least one selected from the group consisting of a halogen atom, a hydroxyl group, a thiol group, an amine group, a nitro group, a cyano group The base of the group is replaced. The term "alkoxy" is used herein to include -0-alkyl, wherein "alkyl" is as defined above. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo group Base, for example, trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, M-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2 , 2 · trichloroethyl. The term "alkylthio" is used herein to include -S-alkyl, of which "alkyl" (please read the phonetic note on the back? Then fill out this page), install----book-t China National Standard (CNS) A4 Specification (210 X 297 mm) 1308912 A7 B7 V. Invention Description (), as defined above. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl '2,2,2-trimethylethyl or substituted with at least one halo group a base such as trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, 1, didimethyl-2,2-dibromoethyl, 1,1-dimethyl-2, 2,2-trichloroethyl. The term "homo-amino group" is used herein to include -NH, or -N (hospital) 2, wherein "alkyl" is as defined above. Preferred alkyl groups are methyl, ethyl, propyl, n-propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or at least one Halogen-substituted group. The term "aryl" is used herein to include an organic group derived from an aromatic hydrocarbon by removal of a hydrogen atom, such as phenyl, phenoxy, naphthyl, aralkyl 'benzyl, optionally 1 Up to 5 selected from a halogen atom, a hydroxyl group, a decyl group, an amine group, a nitro group, a cyano group, a decyl group, a decyloxy group, a sulfonyl group, a sulfinyl group, an alkylamino group, a carboxyl group, an ester group, and an ether. , amidino, sulfonate, sulfonylamino, alkylsulfonyl, alkoxycarbonyl, alkylsulfinyl, alkylthio, oxyester, oxoamine, aryl, (CVC6 Substituent substitution of a group consisting of an alkoxy group, a (c6-c1Q) aryloxy group, and a (C6-C1Q) aryl group. The aryl group is composed of 1 to 3 rings, preferably 1 ring, and 2 to 30 carbon atoms and preferably 6 to 10 carbon atoms. Preferred aryl groups are phenyl, phenyl, cyanophenyl, nitrophenyl, methoxyphenyl, naphthyl, benzyl 'halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl Base, 2-phenylethyl. The term "arylamino" is used herein to include -NH aryl or -N(aryl) 2 group, wherein "aryl" is as defined above. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, naphthyl, halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2 _Phenylethyl. This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) (please read the notes on the back and fill out this page). ** ^1 ^1 ·_1·-fn nnn _ Ministry of Economics Intellectual Property Bureau of Staff Consumer Cooperatives Printed 1308912 ^____ Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperatives Printed A7 B7 Invention Description () The term 'aryloxy' is used here to include -0-aryl, where "aryl" is defined As before. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, benzyl, halobenzyl, cyanobenzyl, methoxy; benzyl, nitrobenzyl, 2 - phenylethyl. The term "arylthio" is used herein to include -S-aryl, wherein "aryl" is as defined above. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, benzyl, halobenzyl, cyanobenzyl, methoxy; benzyl, nitrobenzyl, 2 - phenylethyl. The term "halogen atom" is used herein to include Cl, Br, F, I atoms. The term "hydroxy" is used herein to mean the formula -0H. The term "base" is used herein to mean the -SH group. The term "cyano" is used herein to mean the formula -CN. The term "nitro" is used herein to mean the formula -N〇2. The term "amine" is used herein to mean the formula ΝΗ2 group. The term "carboxy" is used herein to mean the formula -C00H. The term "sulfonic acid group" is used herein to mean the formula -S03H group. The term "sulfonamide" is used herein to mean the formula -so2nh2. The term "heteroaryl" is used herein unless otherwise indicated, otherwise it means that the "aryl" as defined above carries at least one ruthenium, s and/or N 岔 carbene ring structure, such as Z π 固定, furan. Base, pyridyl, thienyl, isodentate, imidazolyl, benzimidazolyl, tetrazolyl, pyridinyl, pyrimidinyl, quinolyl, isoquinolinyl, isobenzofuranyl And thienyl, pyrazolyl, fluorenyl, isodecyl, fluorenyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzothiazolyl, or benzoxazolyl, selective Up to 5 points - 7 - This paper scale applies to China National Standard (CNS) A4 specifications (210 X 297 mm) — i—I — Pack —! — Order --------- (Read first Note on the back page again) 1308912 A7 __B7___ V. Description of invention (6) (Please read the note on the back and fill out this page) Do not choose from hydroxyl, halogen, sulfhydryl, amine, nitro, cyanide Base, fluorenyl, decyloxy, sulfonyl, sulfinyl, alkylamino, carboxyl, ester, ether, decyl, sulfonate, sulfonamide, alkyl sulfonate Substituent substitution of a group consisting of a group, an alkoxycarbonyl group, an oxyester group, a oxonium group, an alkoxycarbonyl group, a (Q-Cs) alkoxy group, and a (c^c5)alkyl group. "Aralkyloxy" The term is used herein to denote the radical of the formula aryl-(anthracene-alkyl)-. Preferred aralkyl is benzyl, halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2-phenethyl, diphenylmethyl, (4-methoxyphenyl)diphenylmethyl. The term "mercapto" is used herein to mean a carboxylic acid group, and thus includes alkyl-CO-, aryl. a group of a base-CO-, a heteroaryl-CO-, an aralkyl-CO- group, wherein each hydroxyl group is as defined. The preferred alkyl group is a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, Iso- or tert-butyl, 2,2,2-trimethylethyl or a group substituted with at least one halo group. Preferred aryl is phenyl, phenyl, cyanophenyl, nitro Phenyl, methoxyphenyl, benzyl, halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2-phenylethyl. Ministry of Economic Affairs, Intellectual Property Office, employee consumption cooperative, printing "oxygen oxime" The term "base" is used herein to mean a carboxylic acid group, and thus includes an alkyl-C0-0-, aryl-C0 group. a group of -0-, heteroaryl-CO-O-, aralkyl-C0-0-, wherein each hydroxy group is as defined herein. Preferably, the alkyl group and the aryl group are as defined for the fluorenyl group. The term "s-alkyl" or "so2-aryl" is defined as "base group" and "square group" as defined above. Preferred bases are methyl, ethyl, propyl and iso a propyl group, a butyl group, an iso- or a tri-butyl group, a 2,2,2-trimethylethyl group or a group substituted with at least one halo group. Preferably, the aryl group is a phenyl group, a halophenyl group or a cyanogen group. Phenyl, nitrophenyl, methoxyphenyl, benzyl, halobenzyl, cyan-8- This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1308912 A7 B7 Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed invention description () benzyl, methoxybenzyl, nitrobenzyl, 2-phenylethyl. The term "sub-expansion" refers to the formula -S0 - the base of the yard or the base of _s0_aryl. The definitions of "hospital base" and "aryl" are as before. Preferably, the base is methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo group base. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, yl, halo; cyanobenzyl, methoxybenzyl, nitrobenzyl ' 2 - phenylethyl. The term "ester group" means the formula - C00 - or the base of -C00-aryl group, wherein "alkyl" and "aryl" are as defined above. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo group base. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, henyl, halooctyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2 - phenylethyl. The term "oxyester" means a radical of the formula -o-coo-alkyl or -O-C00-aryl, wherein "alkyl" and "aryl" are as defined above. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo group base. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, benzyl, benzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2 - phenylethyl. The term "ether group" means a group of the formula alkyl 〇-alkyl or alkyl-0-aryl or aryl-fluorene-aryl, wherein "alkyl" and "aryl" are as defined above. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo group base. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, -9-. The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297). —*—装--------订---------AWI (please read the note on the back first? Then fill out this page) Oxygenamine-based Ministry of Economic Affairs Intellectual Property Bureau Staff Consumption Cooperative Printed 1308912 A7 B7 V. DESCRIPTION OF THE INVENTION () Benzyl, halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2-phenylethyl. The term "amylamine" means a radical of the formula _C0NH2_ or -C0NH or _C0N(alkyl)2 or -CHNH aryl or _C〇N(square)2, wherein "alkyl" and " "Aryl" is defined as before. Preferably, the alkyl group contains from 1 to 4 carbon atoms and the aryl group contains from 6 to 10 carbon atoms. Preferably, the base is methyl 'ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo base. Preferred aryl groups are phenyl 'halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, benzyl, halobenzyl, cyanobenzyl, methoxybenzyl, nitrobenzyl, 2 - phenylethyl. The word indicates the formula -0-CONH2- or -0-C0NH alkyl or -0-C0N(alkyl) 2 or -〇-C〇NH aryl or -0-C0N(aryl) 2, wherein "Base" and "aryl" are as defined above. Preferably, the alkyl group contains from 1 to 5 carbon atoms and the aryl group contains from 6 to 8 carbon atoms. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo group base. Preferred aryl groups are phenyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, benzyl, halobenzyl, cyanyl, methoxyoctyl, nitropropenyl, 2 - phenylethyl. Preferably R1 is methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl or substituted with at least one halo group , for example, trifluoromethyl, trichloromethyl, 2,2,2-trichloroethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2, 2,2-trichloroethyl. Preferably, R2, R3 and R4 are each independently hydrogen or a halogen atom or methyl, ethyl, propyl 'isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl Or .10. This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) (please read the notes on the back and fill out this page) I. Install 1308912 Α7 Β7 V. Invention Description () a group substituted with at least one halo group, such as trifluoromethyl, trichloromethyl, 2.2.2-trichloroethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-di Methyl - (Please read the notes on the back and fill out this page) 2.2.2- Trichloroethyl. Preferably R5 and R6 are methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl. Preferably R7 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl, methoxy, ethoxy , phenyl, benzyl, or a group substituted with at least one halo group such as trifluoromethyl, chlorophenyl. Preferably R8 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso- or tert-butyl, 2,2,2-trimethylethyl, phenyl, benzyl, or The group substituted with at least one halo group such as trifluoromethyl, chlorobenzyl or where X is -CN. Unless otherwise stated, the compounds of formula (A) described herein, whether individually or collectively, include geometric isomers, namely Z (Zusanimen) and E (Entgegen) isomers and Its mixture (racemic mixture). The Intellectual Property Office of the Ministry of Economic Affairs, the Consumers' Cooperatives, prints the Z (Simmon) and E (Anjiu) isomers of the compound of formula (A) for the asymmetric hydrogenation method described below (wherein R1 is methyl, R2 and R4) The best results are obtained for Η and X is -CONH2 or -COOME or -COOEt or -COOH. In this group, compounds in which R3 is a hydrogen, an alkyl hydrazide* (particularly a difluorovinyl group) are particularly suitable: ( — ............ . < A characteristic aspect of the invention relates to a method for preparing a compound of the formula (A), which comprises the following reaction: -11- The paper scale is applicable to the Chinese national standard (εΝέ) Α 4 specification (210 X 297 gong) PCT) 1308912 Ministry of Economic Affairs Intellectual Property Office Staff Consumer Cooperative Printed A7 B7 10, Invention Description () Compound of formula (A) where X is -CONR5R6 or -COOR7 or -CO-R8 or CK 'can be conveniently passed through the formula The α-ketocarboxylic acid derivative of (C) wherein R1 and X are as defined above, and the pyrrolidone of the formula (D) wherein R, R3, and R4 are as defined above, and are prepared according to the following reaction scheme (1). .
反應圖(1) 通式(Α)化合物此處X爲-COOR7可方便地經由通式(C’) α -酮基羧酸衍生物此處X爲-COOR7與通式(D)之吡咯啶 酮根據如下反應圖(2)反應製備。Reaction Scheme (1) Compound of the formula (Α) wherein X is -COOR7 is conveniently via the formula (C') α-ketocarboxylic acid derivative, where X is -COOR7 and pyrrolidine of the formula (D) The ketone was prepared according to the reaction of the reaction scheme (2) shown below.
反應圖(2) 適當反應條件涉及回流使用甲苯。結果所得化合物(Α) 中,R7方便由Η轉成烷基或由烷基轉成Η。 通式(C)或(C’)衍生物及通式(D)吡咯啶酮爲業界人士眾 所周知,且可根據參考文件所述合成製備,例如參考「雜 環族化學手冊」作者A. Katrisky,波加蒙(Pergamon), 1 985(第4章)以及「理解雜環族化學」作者A. Katrisky及 C.W. Rees,波加蒙,1984(第 4 卷,第 3.03 及 3.06 章)。 -12- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 1308912 A7 B7 11五、發明說明() 通式(A)化合物此處X爲-CONH2或-CONFER6可方便地 經由將對應酸(式(A)化合物此處X爲C02H)轉成醯氯, 隨後接著氨解或與通式NHR5R6之第一或第二胺反應製備 。如下二反應圖(3及4)說明此種方法。Reaction Scheme (2) Appropriate reaction conditions involve the use of toluene under reflux. As a result, in the obtained compound (Α), R7 is conveniently converted from hydrazine to alkyl group or from alkyl group to hydrazine. The general formula (C) or (C') derivatives and the general formula (D) pyrrolidone are well known in the art and can be prepared synthetically according to the references, for example, by reference to the "Heterocyclic Chemistry Handbook" by A. Katrisky. Pergamon, 1 985 (Chapter 4) and "Understanding Heterocyclic Chemistry" by A. Katrisky and CW Rees, Pogmont, 1984 (Vol. 4, Chapters 3.03 and 3.06). -12- This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) (please read the notes on the back and fill out this page) 1308912 A7 B7 11 V. Inventions () General formula (A) The compound wherein X is -CONH2 or -CONFER6 is conveniently converted to the hydrazine chloride by the corresponding acid (the compound of formula (A) where X is CO 2 H), followed by aminolysis or the first or second amine with the formula NHR5R6. Reaction preparation. This method is illustrated by the following two reaction diagrams (3 and 4).
(請先閱讀背面之注意事項再填寫本頁) I·裝 經濟部智慧財產局員工消費合作社印製 反應圖(4) 此等反應較佳係使用PC15進行獲得醯氯,接著爲無水 氨或式HNR5R6之第一或第二胺反應獲得所需烯醣胺醯胺。 通式(A)化合物此處X爲-COOR7可方便地由將反應圖(2) 所得對應酸(化合物(A),此處X爲COOH)轉成醯氯,隨後 使用式R7-〇H化合物(醇),此處R7定義如前進行醇解製 備。(參考反應圖5) -13- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 A7 B7 五(Please read the precautions on the back and fill out this page.) I·Installation of the Ministry of Economic Affairs, Intellectual Property Office, Staff Cooperatives, Printing Reaction Chart (4) These reactions are preferably carried out using PC15 to obtain ruthenium chloride, followed by anhydrous ammonia or The first or second amine of HNR5R6 is reacted to obtain the desired olefinic amine amide. The compound of the formula (A) wherein X is -COOR7 can be conveniently converted from the corresponding acid obtained by the reaction scheme (2) (the compound (A), where X is COOH) to ruthenium chloride, followed by the compound of the formula R7-〇H (Alcohol), where R7 is defined as previously prepared by alcoholysis. (Refer to Reaction Figure 5) -13- This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1308912 A7 B7
PCLPCL
R7-OHR7-OH
R3 RR3 R
反應圖(5) 此等反應較佳係使用PC15進行獲得醯氯,接著使用R7-〇 Η醇解獲得預定酯。 前述反應條件爲業界人士眾所周知。 於另一特徵方面,本發明係有關使用式(Α)化合物作爲 合成中間物。 式(Α)化合物,此處X爲-CONH2作爲將此種化合物氫化 結果形成左堤拉西坦特別令人感興趣。此等化合物之Z(住 沙門)及E(安久占)可進行快速及選擇性之非對稱氫化反應 成爲預定產物之任一種對映異構物。接合R1至分子之鍵 結表示Z異構物或E異構物。 至於特例,使用化合物(A)合成的化合物(B)可根據如下 反應圖(6)說明。 (請先閱讀背面之注意事項再填寫本頁) 裝 # 經濟部智慧財產局員工消費合作社印製Reaction Scheme (5) These reactions are preferably carried out using PC15 to obtain hydrazine chloride, followed by the use of R7-indole hydrazide to obtain a predetermined ester. The foregoing reaction conditions are well known to those skilled in the art. In another feature, the invention relates to the use of a compound of the formula (Α) as a synthetic intermediate. Compounds of the formula (Α), where X is -CONH2, are of particular interest as hydrogenation of such compounds to form levetiracetam. Z (Simmon) and E (Anjiu) of these compounds can be subjected to rapid and selective asymmetric hydrogenation to any of the desired enantiomers. The bond joining R1 to the molecule represents a Z isomer or an E isomer. As a special case, the compound (B) synthesized using the compound (A) can be explained according to the following reaction scheme (6). (Please read the precautions on the back and fill out this page) 装装# Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing
ITIT
RR
RR
R N 〇R N 〇
X (B) 反應圖(6) 其中R1、R2、R3、R4及X定義如前 -14- 本紙張尺度適用中國國家標準(CNS)A4規格(21G X 297公爱) 1308912 A7 B7 i、發明說明(') 較佳R1爲甲基、乙基、丙基、異丙基、丁基或異丁基 :最佳爲甲基、乙基或正丙基。 較佳R2及R4分別爲氫或鹵原子或甲基、乙基、丙基、 異丙基、丁基、異丁基;及最佳各別爲氫。 較佳丨R3· CrQ烷基、C2-C5炔基、環丙基疊氮基,各 自選擇性經以一或多個鹵原子、氰基、硫氰基、疊氮基、 烷硫基、環丙基、醯基及/或苯基取代;苯基;苯基磺醯 基;苯基磺醯氧基,四唑基,三唑基,噻吩基,呋喃基, 吡咯基,吡啶基,藉此任何苯基部分可經以一或多個鹵原 子、院基、鹵院基、院氧基、硝基、胺基及/或苯基取代X (B) Reaction diagram (6) where R1, R2, R3, R4 and X are defined as before -14 - This paper scale applies to China National Standard (CNS) A4 specification (21G X 297 public) 1308912 A7 B7 i, invention DESCRIPTION (') Preferably, R1 is methyl, ethyl, propyl, isopropyl, butyl or isobutyl: most preferably methyl, ethyl or n-propyl. Preferably, R2 and R4 are each independently hydrogen or a halogen atom or methyl, ethyl, propyl, isopropyl, butyl, isobutyl; and most preferably hydrogen. Preferably, R 3 · CrQ alkyl, C 2 -C 5 alkynyl, cyclopropyl azide, each optionally having one or more halogen atoms, a cyano group, a thiocyano group, an azide group, an alkylthio group, a ring a propyl group, a fluorenyl group and/or a phenyl group; a phenyl group; a phenylsulfonyl group; a phenylsulfonyloxy group, a tetrazolyl group, a triazolyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyridyl group, Any phenyl moiety may be substituted with one or more halogen atoms, a court base, a halogen-based group, an alkoxy group, a nitro group, an amine group, and/or a phenyl group.
;最佳爲甲基、乙基、丙基、異丙基、丁基或異丁基。I ---1 較佳 X 爲-COOH 或-COOMe 或-COOEt 或-CONH2 ;最佳 爲-CONH2。 式(B)化合物可以習知方式呈自由態形式單離或轉變成 其醫藥可接受性鹽,或反之亦然。 較佳藉由通式(B)之化合物中個別化合物具有式(B ’)、 (B,,)及(B,,,)。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印制衣Most preferred is methyl, ethyl, propyl, isopropyl, butyl or isobutyl. I ---1 Preferably X is -COOH or -COOMe or -COOEt or -CONH2 ; optimally -CONH2. The compound of formula (B) may be isolated or converted into its pharmaceutically acceptable salt in a free form in a conventional manner, or vice versa. Preferably, the individual compounds of the compound of the formula (B) have the formula (B '), (B,,) and (B,,,). (Please read the notes on the back and fill out this page.) Ministry of Economic Affairs, Intellectual Property Bureau, Staff Consumer Cooperatives, Printed Clothes
(B,)(B,)
(B-) 式(B)化合物適合用於治療癲癇及相關疾病。根據另 -15- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 1308912 Α7 Β7 18五、發明說明() 如業界人士已知,視取代形式決定,並非全部通式(A) 及(B)化合物皆可形成鹽,故述及「醫藥可接受性鹽」僅 應用至具有形成鹽能力之通式(A)或(B)化合物。 下列實例僅供舉例說明之用,而非意圖也非解釋爲限制 本發明。業界人士了解可未超出本發明之精髓或範圍對下 列實例之例行變化及修改。 實例1 前驅物A 1之製備係參照反應圖7,經由a -酮基丁酸與 吡咯啶酮於回流加熱進行,70%粗產率。z:E表示Z異構 物量對E異構物量之比。(B-) The compound of the formula (B) is suitable for the treatment of epilepsy and related diseases. According to the other -15- This paper scale applies the Chinese National Standard (CNS) A4 specification (210 x 297 mm) 1308912 Α7 Β7 18 5, invention description () As the industry knows, depending on the substitution form, not all formulas ( Both A) and (B) compounds can form salts, so that "pharmaceutically acceptable salts" are applied only to the compounds of formula (A) or (B) which have the ability to form salts. The following examples are for illustrative purposes only and are not intended to be limiting of the invention. Those skilled in the art will appreciate that routine variations and modifications of the examples below may be made without departing from the spirit or scope of the invention. Example 1 The preparation of precursor A 1 was carried out by refluxing with a-ketobutyric acid and pyrrolidone under reflux, 70% crude yield. z: E represents the ratio of the amount of Z isomer to the amount of E isomer.
OHOH
Η I τ 甲苯,回流’丁-史塔克 70% (請先閱讀背面之注意事項再填寫本頁) I-裝 Γ i 經濟部智慧財產局員工消費合作社印制衣 OH 再結晶 OH Γ 丫 N 〇 内酮·16ν〇1 丫 70% Z:E=80:1 前驅物A1 Z:E= 149 :1 熔點 165 - 166pC 反應圖7 粗產物由丙酮再結晶’ 70%產率。雙鍵幾何係基於與類 •20· 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 A7 B7 19五、發明說明()似結構之已知化合物1 H-NMR(核磁共振)光譜資料之交互 關係被指定爲Z。實例2前驅物A2係使用重氮甲烷於THF製自A 1。觀察得蒸 餾期間Z-E比由80:1變化至29:1(參考反應圖8)。 on OMe ,Ν ο Ο 1. CH2N2, THF, 100 % I.蒸餾,80% 前驅物A1 Z : E = 80 : 1 前驅物A2 Z : E = 29 :; 反應圖8前驅物A2 ’之E異構物如反應圖9所述係使用乙醇、二 環己基甲二醯亞胺(DCC)以及二甲基胺基吡啶(DMAP)而得 自前驅物A1之Z異構物。Η I τ Toluene, reflux 'Ding-Stark 70% (please read the note on the back and fill out this page) I-Installation i Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed OH Recrystallized OH Γ 丫N Indoleone·16ν〇1 丫70% Z:E=80:1 Precursor A1 Z:E= 149 :1 Melting point 165 - 166pC Reaction Figure 7 Crude product recrystallized from acetone '70% yield. The double-key geometry is based on the class of 20%. This paper scale applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 1308912 A7 B7 19 V. Inventive Note () Structure-like compound 1 H-NMR ( The interaction of the NMR spectral data is designated as Z. Example 2 Precursor A2 was prepared from A1 using diazomethane in THF. The Z-E ratio during the distillation was observed to vary from 80:1 to 29:1 (see Reaction Scheme 8). On OMe , Ν ο Ο 1. CH2N2, THF, 100 % I. Distillation, 80% Precursor A1 Z : E = 80 : 1 Precursor A2 Z : E = 29 :; Reaction Figure 8 Precursor A2 'E The structure was obtained from the Z isomer of the precursor A1 using ethanol, dicyclohexylmethyleneimine (DCC) and dimethylaminopyridine (DMAP) as described in Reaction Scheme 9.
EtOH(3 當量) DCC(1 當量) .二. •n -_DMAP(0.·]當量),丁办(加容積) U 室溫(r.t),24小時 . 〇 —----^EtOH (3 eq.) DCC (1 eq.). 2. n - _DMAP (0.·) equivalent), Ding (plus volume) U Room temperature (r.t), 24 hours. 〇 —----^
(請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 前驅物A2, E異構物 …. 100。/〇 羞率前驅物A 1之酯化也以小規模使用PC15於THF然後使用甲醇進行,獲得預定甲酯(Z:E = 5:1),參考反應圖10 ° 前驅物A1 Z異構物 反應圖 -21. 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱) 1308912 A7 B7 五、發明說明( Τ on ο Ν、/Ο 1. PC15 當量,THF,()》C 2. MehH 1當量,毗啶 OMe(Please read the notes on the back and fill out this page.) Printed by the Ministry of Economic Affairs, Intellectual Property Bureau, Staff Consumer Cooperative, Precursor A2, E Isomers .... 100. The esterification of the precursor A 1 is also carried out on a small scale using PC15 in THF followed by methanol to obtain a predetermined methyl ester (Z: E = 5:1). Reference reaction scheme 10 ° precursor A1 Z isomer Reaction Figure-21. This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 public) 1308912 A7 B7 V. Description of invention ( Τ on ο Ν, /Ο 1. PC15 equivalent, THF, () C 2. MehH 1 equivalent, pyridinium OMe
前驅物A2 E : Z = 5 : 1 前驅物A1 反應圖1 0 眚例 前驅物A2亦係經由酮基丁酸甲酯與吡咯啶酮於回流甲 苯於催化量之磷醯氯存在下反應製備,參考反應圖11。Precursor A2 E : Z = 5 : 1 Precursor A1 Reaction Figure 10 The precursor A2 is also prepared by reacting methyl ketobutyrate with pyrrolidone in refluxing toluene in the presence of a catalytic amount of phosphonium chloride. Refer to Reaction Figure 11.
Ο (請先閱讀背面之注意事項再填寫本頁) 裝 I n I . 經濟部智慧財產局員工消費合作社印制农 前驅物Α2 Ζ:Π = 6:1 反應圖1 1 酮基丁酸之酯化係使用甲醇遵照參考文獻方法或使用重 氮甲院進行。隨後縮合反應獲得前驅物Α2,60%產率。此 種方法比較經由前驅物A 1之途徑(反應圖8)獲得較高ε異 構物含量。兩種途徑皆可製備前驅物A 2之其它酯衍生物。 -22- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 A7 B7 五、發明說明(23) 表1Ο (Please read the note on the back and fill out this page) Install I n I. Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed Agricultural Precursor Α 2 Ζ: Π = 6:1 Reaction Figure 1 1 Ketobutyric acid ester The chemical system was carried out using methanol according to the reference method or using a diazotamine. Subsequent condensation gave a precursor Α 2, 60% yield. This method compares the higher ε isomer content obtained via the route of precursor A 1 (reaction Figure 8). Other ester derivatives of the precursor A 2 can be prepared in both ways. -22- This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1308912 A7 B7 V. Invention description (23) Table 1
St. Ma. Am. 毫克 .催化劑 Cou. Loa. Solv. 112 Pres. (、.v. % % A1 100 (S,S)-Et*DUPHOS OTf(-) 5.0 EtOH 4 100 95 A1 100 (S.S)-BPPM 〇Tf(-) 5.0 EtOH 1 68 64 A1 100 (R,R)-DIPAMP BF4(-) 5.0 DCM 4 100 92 A2 (Z) 200 (S,S)-Et-DUPHOS 〇Tf(-) 2.0 EtOH 4 100 93.8 A2 (Z) 200 (S,S)-Et-DUPHOS ΟΤΓ(~) 0.5 EtOH 4 100 99.1 A2 (Z) 200 (S,S)-Me-DUPHOS OTf(-) 1,0 EtOH 5 100 98.9 A2 (Z) 300 (S,S)-Me-DUPHOS OTf(-) 2.0 IPA 5 100 97.9 A2,(E) 200 (SfS)-Me-DUPHOS OTf(-) 0.5 EtOH 5 100 99.4 A2,(E) 300 (S.S)-Me-DUPHOS OTf(-) 0.5 IPA 5 100 94.0 A2 (E) 4000 (S.S)-Me-DUPHOS BF4(-) 0.025 MeOH 5 100 97.4 A2 (Z) 4000 (S.S)-Me-DUPHOS BF4(-) 0.01 MeOH 5 99 99 A2 (Z) 4000 (S.S)-Me-DUPHOS BF4H 0.005 MeOH 5 25 97 A2' (E) 300 (S,S)-BPPM OTf(-) 0.5 MeOH 1 100 -99.3 A2' (E) 300 (S,S)-BPPM OTf(-) 0.5 EtOAc 1 100 -95.2 A2 (E) 300 (S,S)-BPPM OTf(-) 0.5 甲苯 1 100 -96.2 A2 (Z) 200 (RR)-DIPAMP BF4H 2.0 EtOAc 5 100 94.5 A2,(E) 200 (R,R)-DIPAMP BF4(-) 0.5 EtOAc 5 92 96.5 表中 ,St. Ma表示起始物料 ;Am 表示量 ;Cou.表示相 對離子 ;Loa.表示載荷莫耳% ; Solv .表示溶劑, H2 Pres. (請先閲讀背面之注意事項再填寫本頁) 裝 —* n t n I - 經濟部智慧財產局員工消費合作社印製 表示氫壓(大氣壓);以及C.V.表示轉化率。 實例6 :前驅物A3之非對稱氫化 使用如實例5之相同方法;多種鍺及釕催化劑經過篩選 ,參考反應圖1 3及表2之代表性結果。 -25- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 A7 B7 五、發明說明( 榭$ 歡m u μ頰 §1:1 E^rt •SOJa CSH 馨 懸 ο/οοε •rtoq •300 A° Z6 L, s 8_ε6 ·寸 6 ε6 〇卬 扪' Lm_ 001οοι 001 001001 001 §1 06-0S 001 001St. Ma. Am. mg. Catalyst Cou. Loa. Solv. 112 Pres. (,.v. % % A1 100 (S,S)-Et*DUPHOS OTf(-) 5.0 EtOH 4 100 95 A1 100 (SS) -BPPM 〇Tf(-) 5.0 EtOH 1 68 64 A1 100 (R,R)-DIPAMP BF4(-) 5.0 DCM 4 100 92 A2 (Z) 200 (S,S)-Et-DUPHOS 〇Tf(-) 2.0 EtOH 4 100 93.8 A2 (Z) 200 (S,S)-Et-DUPHOS ΟΤΓ(~) 0.5 EtOH 4 100 99.1 A2 (Z) 200 (S,S)-Me-DUPHOS OTf(-) 1,0 EtOH 5 100 98.9 A2 (Z) 300 (S,S)-Me-DUPHOS OTf(-) 2.0 IPA 5 100 97.9 A2, (E) 200 (SfS)-Me-DUPHOS OTf(-) 0.5 EtOH 5 100 99.4 A2,( E) 300 (SS)-Me-DUPHOS OTf(-) 0.5 IPA 5 100 94.0 A2 (E) 4000 (SS)-Me-DUPHOS BF4(-) 0.025 MeOH 5 100 97.4 A2 (Z) 4000 (SS)-Me -DUPHOS BF4(-) 0.01 MeOH 5 99 99 A2 (Z) 4000 (SS)-Me-DUPHOS BF4H 0.005 MeOH 5 25 97 A2' (E) 300 (S,S)-BPPM OTf(-) 0.5 MeOH 1 100 -99.3 A2' (E) 300 (S,S)-BPPM OTf(-) 0.5 EtOAc 1 100 -95.2 A2 (E) 300 (S,S)-BPPM OTf(-) 0.5 Toluene 1 100 -96.2 A2 (Z 200 (RR)-DIPAMP BF4H 2.0 EtOAc 5 100 94.5 A2, (E) 200 (R,R)-DIPAMP BF4(-) 0.5 EtOAc 5 92 96.5 Table, St. Ma Show starting material; Am for quantity; Cou. for relative ion; Loa. for load mol%; Solv. for solvent, H2 Pres. (Please read the back note first and then fill out this page) Pack—* ntn I - The Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed indicates hydrogen pressure (atmospheric pressure); and CV indicates conversion rate. Example 6: Asymmetric hydrogenation of precursor A3 The same procedure as in Example 5 was used; various rhodium and ruthenium catalysts were screened, with reference to the representative results of Figure 13 and Table 2. -25- This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) 1308912 A7 B7 V. Invention description (榭$ mu μ mu μ cheek § 1:1 E^rt • SOJa CSH 悬 οο Οοε •rtoq •300 A° Z6 L, s 8_ε6 ·inch 6 ε6 〇卬扪' Lm_ 001οοι 001 001001 001 §1 06-0S 001 001
Uooz-S9 - t ZI 91 0寸 91 QL β SI SI 91 91 寸 I 寸 寸 寸 寸 寸 寸 ·寸 0寸 0寸 01 0Z οε οζ 03 0Ζ 03 SUQ SUQHOS Η23 χοΰ §α SOQ SOQ I-O^E/HO】^ Μ〇δ (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 釀領 傾w εν _鎰 •s (-U10 UH s〇HdD9s-(s.s) 00^ ·0 (-UH〇 uh SOHdna-s-(s.s) OS ·0 【-HVLO gsdds-(s*s} 〇00Mo.l (_)sms <ί"ν&αέ·Η) oos s Hsm § dwvdIa-H.H) 00^ z 00^ 0·Ι')sms diwdia 丨(H*&00^ ·0 H2S s dIATVdIa-(H*H) Cos 91 (丨)。v〇 CIVMISAH) 00^ •z: 【-pvo PH dvMIS-(H) 001 裝--------訂--------- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -2 1308912 A7 B7 26 五、發明說明() 抑制催化作用。藉配位溶劑抑制催化作用提示A3爲不良 配位基質,特別比較其它α -醯基胺基丙烯酸衍生物爲不 (請先閲讀背面之注意事項再填寫本頁) 良配位基質。 雖言如此,於DCM獲得絕佳結果。如所見,於此溶劑 於0.5至15克規模可一致地達成97至98%e.e.對映選擇 性。於EtOAc-DCM溶液混合物及甲苯可獲得其它有用展 望的結果。 表 3 :使用[Rh-COD -(S,S)-Et-杜弗斯]OTf 氫化 A3 數量 A3 毫克 催化劑 莫耳% 溶劑 溶劑 容積 反應 時間 (小時) C.V. % e.e, % 500 1.0 AcOEt/DCM 30 ^ . 1 17 95 96 500 1.0 DCM 20 17 100 97 500 0.5 DCM 30 16 99 98 500 0.5 DCM 40 16 100 97 500 2.5 DCM 40 17 100 97 10000 1.0 甲苯 30 65 93 92 500 1.0 甲苯 30 16 95 95 表中C.V.表示轉化率。 經濟部智慧財產局員工消費合作社印製 A.前驅物A1之製備:(Z)-2-(2-氧基四氫-1H-1-吡咯基)·2-丁烯酸(前驅物Α1) 配備有磁攪棒及丁-史塔克凝氣瓣之1升燒瓶內進給2-氧基丁酸(25克,245毫莫耳),曱苯(500毫升,20容積) -28- 本紙張尺度適用中國國家標準(CNS)A〇ik (210 X 297公f ) 13〇8912 經濟部智慧財產局員工消費合作社印製 A7 B7 :r 27 i、發明說明() 及2-吡咯啶酮(37.2毫升,490毫莫耳,2當量)。反應混 合物於回流下攪拌伴以經由丁 -史塔克凝氣瓣共沸蒸餾去 除水歷經5.5小時。然後溶液濃縮至約90毫升(3.6容積) 且任其緩慢冷卻至周圍溫度。灰白色固體於約55 °C開始由 溶液中沉澱出。固體經過濾,濾餅以甲苯(2x1容積)洗滌 ,接著以二氯甲烷(3x1容積)洗滌,及於過濾器真空脫水 5分鐘獲得粗物料(28克,70%產率)。粗產物回流溶解於 丙酮(450毫升,16容積),緩慢冷卻至周圍溫度及任其於 -15至-2CTC再結晶12小時時間。獲得純產物呈白色結晶 固體(21克,50%總產率)。 熔點(m _ p ·) 1 6 5 _ 5 -1 6 6 °C。 ;H-NMR (CDC13):(5(化學位移)2·13(5Η,雙峰(d)及多峰), 2·51(2Η,三峰(t)),3_61(2H, t),6.27(lH,四峰(q)),8 至 10 (1H,寬);E-異構物信號,δ 1.85(3H, t),7·18(1Η,q)。 13C NMR(MeOH-d4):5 14.7, 1 9.6, 32.1, 1 5.4, 1 30.8, 137.7, 166.6, 177.9 。 Z:E 比 149:1,藉1H NMR 測定。 薄層層析(TLC):Si〇2,甲苯/AcOH/MeOH(4:l:〇_5),UV 及茴香醛染色。 B.前驅物A2之製備:(Z)-2-(2-氧基四氫-1H-1-吡咯基)-2-丁 烯酸甲酯(前驅物A2) 前驅物Al(12克,71毫莫耳)於〇-5°C溶解於THF(240 毫升,20容積)。重氮甲烷於醚溶液(200毫升,約78毫莫 耳,1 · 1當量)分成數份添加至反應混合物,溫度維持低於 -29- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----------裝--------訂--------- (請先閱讀背面之注意事項再填寫本頁) 1308912 A7 B7 28 五、發明說明() 5 °C。藉最後一份反應劑,反應混合物轉成黃色。又於低 溫攪拌3 0分鐘’然後任其溫熱。剩餘微量重氮甲烷藉逐 滴添加極稀乙酸於THF破壞至黃色溶液變無色。反應混 合物經真空濃縮,粗物料經蒸餾(93-94°C , 0.01毫米汞柱) 獲得純產物(9.44克’ Ή%)呈無色油,其於1 〇°c以下冷卻 時固化。 *H NMR(CDC13): 5 2.0(3H, d)5 2.1(2H, m), 2.43(2H, t), 3.54(2H,t),3.76(3H, s),5.96(1H,q) ; E-異構物信號,5 1·75(3Η,t)及 7·05(1Η, q)。 13C NMR(MeOH-d4): (5 14.4, 1 9.7, 32.5 1, 52.6, 1 30.1, 165.6, 177.4 。 Z:E 比 29:1,藉 H1 NMR 測定。 C. 2-氧基丁酸甲酯之製備 2-氧基丁酸(15克)使用庫久路(Kugelruhr)裝置於減壓下 蒸餾(84°C,20毫米汞柱)獲得14克純物料。經蒸餾的2-氧基丁酸 (14克)溶解於甲醇(無水,20毫升,14容積) ,及二氯乙烷(無水,80毫升,5.7容積)於數滴乙烷磺酸 存在下進行。反應混合物於惰性氣氛下回流攪拌1 8小時 。然後任冷卻,以硫酸鎂脫水,過濾及真空濃縮。粗料藉 蒸餾純化(沸點76°C,20毫米汞柱)獲得純產物呈無色油 (7.53 克,48%產率)。 NMR (CDC13):<5 0.88(3H,d),2.66(2H,q),3.63(3H,s) 參考生物化學,2670, 1 917。 D. (Z)-2-(2-氧基四氫-1Η-1-吡咯基)-2-丁烯酸甲酯(前驅物 -30- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝 訂---------· 經濟部智慧財產局員工消費合作社印制衣 1308912 A7 B7 29 五、發明說明() A2)之製備 .裝 (請先閱讀背面之注意事項再填寫本頁) 配備有磁攪棒及丁-史塔克凝氣瓣之10 〇毫升燒瓶內進 給2-氧基丁酸甲酯(7.5克,73毫莫耳),甲苯(50毫升,7 容積)及2 -吡格U定酮(8.4毫升,111毫莫耳,1.5當量)接著 逐滴添加磷醯氯(1.6毫升,20毫莫耳,0.2 7當量)。反應 混合物於回流下攪拌伴以經由丁-史塔克凝氣瓣共沸蒸餾 去除水歷經8小時。冷卻後溶液以1 0 %硫酸氫鉀水溶液 (2x3容積)洗滌。水相以氯化鈉飽和,及以甲苯χ6容 積)回萃取。合倂有機相以硫酸鎂脫水,過濾及真空濃縮 獲得粗物料(7.5克)呈橙色動相油。粗油經蒸餾(92-94t , 0.1毫米汞柱)獲得純產物(4.7克,60%)呈無色油。 Z:E 比 6:1,藉1H NMR 測定。 Ε·(Ε)-2-(2-氧基四氫-1Η-1-吡咯基)-2-丁烯酸甲酯(前驅物 A2)之製備 經濟部智慧財產局員工消費合作社印製 配備有磁攪棒之無水100毫升燒瓶內進給Z-A1(2克, 11.8毫莫耳)’乙醇(2.2毫升,37.3毫莫耳),四氫呋喃 (THF,40毫升,20容積)及二甲基胺基吡啶(DM AP,150 毫克’ 1.23毫莫耳),燒瓶係置於氮氣氣氛下。反應混合 物於加入二環己基甲二醯亞胺(DCC,2.46克,11.9毫莫 耳)前冷卻至0°C,然後加熱至周圍溫度。反應混合物激烈 攪拌21小時。隨後加入己烷(40毫升.)至沉澱固體。沉澱 經過濾出及濾液經真空濃縮獲得3.03克無色液體油。油 於水(40毫升)使用二氯甲烷(Dcm,40毫升然後2x20毫 升)洗滌’溶劑藉硫酸鈉脫水及真空濃縮獲得2克E-A2乙 -31- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 五、發明説明(3G) 酯(100%產率)。 F.則驅物A3之製備:(z)-2-(2-氧基四氫-1H-1-吡咯基)-2-丁 烯醯胺(前驅物A 3 ) 架設20升凸緣瓶供於惰性氣氛下攪拌且進給a :! (222克 ’ 1.313莫耳’ 1當量)及無水thf(7.0升,30容積)。任 反應混合物冷卻至5 °C以下,分成數份添加五氯化磷(3 00 克’ 1.44莫耳’ ].1當量),反應溫度維持低於丨〇它。反應 混合物於-5至0°C攪拌1小時’任其溫熱至;! 5 t而溶解剩 餘五氯化磷’然後冷卻0 °C以下。塡裝乾冰/丙酮之冷凝器 嵌合至燒瓶上’氨氣(約200克)緩慢通過溶液,維持溫度 低於1 5°C。懸浮液又攪拌1 5分鐘,藉通過氮氣數分鐘去 除過量氨氣。加入甲醇(3.7升,17容積),反應混合物回 流1 · 5小時’然後冷卻至3 0°C以下過濾,以THF/甲醇(2:1 ,60 0毫升,約3容積)洗滌。濾液經蒸發獲得黃色固體。 此物質溶解於甲醇(640毫升,約3容積)及乙酸乙酯(440 毫升,2容積)及使用無水急速層析術純化(矽膠,1 1重量 ’ 3.4千克)使用乙酸乙酯/甲醇(6:1)洗提獲得粗產物(288 克)。粗產物由異丙醇(1 . 9升,約8.5容積)再結晶獲得白 色晶體(127克)。固體於真空烘箱於周圍溫度脫水2曰獲 得 A3 (1 1 8 克,54%)。 'H NMR(CDCb +數滴 MeOD): (5 6.75(]H, q),3.5(2H,t), 2·5(2Η, t),2.15(2H, m),1·7(3Η,d),微量雜質。 元素分析C 56.90(57.1 3%理論値);η 7.19 (7.19%理論値);1^ 1 6.3 2(1 6.66%理論値)。 -32- 1308912 五、發明説明(32) 西蘭克試管使用氫氣(5X真空/氫)掃除及於周圍溫度攪拌 1.5小時。澄淸紅橙色溶液經注射器移轉至另一西蘭克試 管(使用氬氣掃除)。催化劑溶液於氬下儲存於°C及直 接用於氫化(T e t r a h e d r ο η,1 2 4 5,1 9 8 4)。 I. [RuhCl(R)-Binap(C6H6)] + Cl —之製備 配備有磁攪棒且於氬氣氣氛下之無水200毫升西蘭克試 管內進給[RuC12(C6H6)]2(0.3 克,0.66 毫莫耳)及(R)-Binap (0.815克,1.3毫莫耳)。加入經除氣的無水苯(20毫升, 60容積)及乙醇(130毫升,3 3 0容積),溶液經除氣(3x真 空/氬氣)。紅橙色懸浮液加熱至5 0-55 °C經45分鐘獲得澄 淸褐色溶液。溶液經西來特(celite)襯墊於氬下過濾入另一 西蘭克試管內。溶劑經真.空蒸發獲得催化劑呈黃色固體 (1.08克,86%),於氬下儲存於0-5 °C (有機化學期干[J, 3064 , 1994) 〇 J. [RuCl(R)-Binap(C6H6)] + BF4_之製備 配備有磁攪棒且於氬氣氣氛下之無水1 00毫升西蘭克試 管內進給[RuCl(R)-Binap(C6H6)] + Cl-(0.45 克,0.52 毫莫耳) 以及經過除氣之無水二氯甲烷(20毫升,44容積)。所得溶 液經除氣(3x真空/氬氣),且經注射器移轉至另一個西蘭 克試管其中含有AgBF4(0.15克,0.77毫莫耳,1.5當量) 於二氯甲烷(]〇毫升,2 2容積)之懸浮液。混合物經激烈攪 拌0 · 5小時,然後於氬氣氣氛下經西來特過濾。濾液經真 空濃縮獲得催化劑呈綠色固體(0.42克,88%),其係於氬 下儲存0-5 °C (有機化學期刊,3064,】994)。 -34- 1308912 經濟部智慧財產局員工消費合作社印製 A7 B7____ 33 ' ~五、發明說明() K-Ru(OCOCH3)2-[(R)-BinaP]之製備 卜 配備有磁擾棒且於氬氣氣氛下之無水200毫升西蘭克試 管內進給[RuC12(C6H6)]2(0.805克,1.60毫莫耳)以及(R)_ Binap(1.89克’ 3_03晕莫耳’ 0.95當量)。加入經除氣之 無水二甲基甲醯胺(30毫升,38容積),溶液經除氣(3><真 空/氬氣)。反應混合物加熱至1 00°C歷1 0分鐘,獲得暗紅 色溶液’然後冷卻至周圍溫度。乙酸鈉(5.2克,63.4毫莫 耳’ 20當量)於甲醇(50毫升,60容積)之除氣溶液進給至 反應容器及攪拌5分鐘。加入除氣水(50毫升,60容積)及 甲苯(25毫升’ 3 0容積),及反應混合物激烈攪拌5分鐘。 甲苯層經注射器移至另一個西蘭克試管(使用氬氣掃除), 及水相以甲苯(2x25毫升)萃取。合倂甲苯溶液以水(4χ 1 0 毫升)洗滌,溶劑經於45°C真空濃縮及真空脫水12小時 (0.1毫米汞柱)。黃褐色固體未經攪拌即溶解於甲苯(25毫 升),緩慢添加己烷(75毫升)而生成第二層於頂上。二相 混合物於周圍放置7小時,然後於0-5°C放置3日。催化 劑結晶出。溶劑於氬氣氣氛下經注射器去除,固體由己烷 (20毫升)洗滌,及真空脫水2小時獲得催化劑呈黃褐色固 體(1.76克,70%)儲存於氬下於0-5t (有機化學期干tj ’ 4053 , 1992) ° L.前驅物A1、A2、A3之非對稱氫化 非對稱氫化反應對各前驅物係遵循相同方案。因此’僅 說明A3之非對稱氫化如後。 前驅物A3之非對稱氫化。 -35- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)Uooz-S9 - t ZI 91 0 inch 91 QL β SI SI 91 91 inch I inch inch inch inch inch inch inch inch 0 inch 0 inch 01 0Z οε οζ 03 0Ζ 03 SUQ SUQHOS Η23 χοΰ §α SOQ SOQ IO^E/HO】^ Μ 〇δ (Please read the note on the back and then fill out this page) Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed brewing collar w εν _镒•s (-U10 UH s〇HdD9s-(ss) 00^ ·0 ( -UH〇uh SOHdna-s-(ss) OS ·0 [-HVLO gsdds-(s*s} 〇00Mo.l (_)sms <ί"ν&αέ·Η) oos s Hsm § dwvdIa-HH) 00^ z 00^ 0·Ι')sms diwdia 丨(H*&00^ ·0 H2S s dIATVdIa-(H*H) Cos 91 (丨).v〇CIVMISAH) 00^ •z: [-pvo PH dvMIS-(H) 001 Pack -------- Order --------- This paper size applies to China National Standard (CNS) A4 specification (210 X 297 mm) -2 1308912 A7 B7 26 V. Description of the invention () Inhibition of catalysis. The inhibition of the catalytic action by the coordination solvent suggests that A3 is a poor coordination matrix, especially compared to other α-mercapto methacrylic acid derivatives. (Please read the back of the note first and then fill out this page) Good coordination matrix. Despite this, excellent results were obtained at DCM. As can be seen, this solvent consistently achieves 97 to 98% e.e. enantioselectivity on a scale of 0.5 to 15 grams. Other useful prospects were obtained from the EtOAc-DCM solution mixture and toluene. Table 3: Hydrogenation of A3 using [Rh-COD -(S,S)-Et-Duffs]OTf A3 A3 mg catalyst Molar % Solvent Solvent volume reaction time (hours) CV % ee, % 500 1.0 AcOEt/DCM 30 ^ . 1 17 95 96 500 1.0 DCM 20 17 100 97 500 0.5 DCM 30 16 99 98 500 0.5 DCM 40 16 100 97 500 2.5 DCM 40 17 100 97 10000 1.0 Toluene 30 65 93 92 500 1.0 Toluene 30 16 95 95 CV represents the conversion rate. Printed by the Intellectual Property Office of the Ministry of Economic Affairs, Staff Consumer Cooperatives. A. Preparation of precursor A1: (Z)-2-(2-oxytetrahydro-1H-1-pyrrolyl)·2-butenoic acid (precursor Α1) 2-oxobutyric acid (25 g, 245 mmol) in a 1 liter flask equipped with a magnetic stir bar and a D-Stark gas valve, benzene (500 ml, 20 volumes) -28- The paper scale applies to the Chinese National Standard (CNS) A〇ik (210 X 297 public f) 13〇8912 Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed A7 B7:r 27 i, invention description () and 2-pyrrolidone ( 37.2 ml, 490 mmol, 2 equivalents). The reaction mixture was stirred under reflux with azeotropic distillation via a D-Stark coagulation valve to remove water for 5.5 hours. The solution was then concentrated to about 90 mL (3.6 vol) and allowed to cool slowly to ambient temperature. An off-white solid precipitated from the solution at about 55 °C. The solid was filtered, and the filter cake was washed with toluene (2×1 volume), then washed with dichloromethane (3×1 volume) and dehydrated under vacuum for 5 minutes to obtain a crude material (28 g, 70% yield). The crude product was refluxed in acetone (450 mL, 16 vol), slowly cooled to ambient temperature and then recrystallized from -15 to -2 CTC for 12 hours. The pure product was obtained as a white crystalline solid (21 g, 50% yield). Melting point (m _ p ·) 1 6 5 _ 5 -1 6 6 °C. ;H-NMR (CDC13): (5 (chemical shift) 2·13 (5Η, bimodal (d) and multimodal), 2·51 (2Η, trimodal (t)), 3_61(2H, t), 6.27 (lH, four peaks (q)), 8 to 10 (1H, broad); E-isomer signal, δ 1.85 (3H, t), 7·18 (1Η, q). 13C NMR (MeOH-d4) : 5 14.7, 1 9.6, 32.1, 1 5.4, 1 30.8, 137.7, 166.6, 177.9. Z:E ratio 149:1, determined by 1H NMR. Thin layer chromatography (TLC): Si〇2, toluene/AcOH/ MeOH (4:1: 〇_5), UV and anisaldehyde dyeing B. Preparation of precursor A2: (Z)-2-(2-oxytetrahydro-1H-1-pyrrolyl)-2-butene Methyl enoate (precursor A2) Precursor Al (12 g, 71 mmol) was dissolved in THF (240 mL, 20 vol) at 〇-5 ° C. Diazomethane in ether solution (200 mL, ca. 78) Millol, 1 · 1 equivalent) is added to the reaction mixture in several portions, the temperature is maintained below -29- This paper scale is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) ------- ---装--------Book--------- (Please read the note on the back and fill out this page) 1308912 A7 B7 28 V. Invention description () 5 °C. The last reaction, the reaction mixture turned yellow. Stir at low temperature for 30 minutes' then let it warm. The remaining traces of diazomethane were added dropwise to dilute acetic acid in THF and the yellow solution became colorless. The reaction mixture was concentrated in vacuo and the crude material was distilled (93-94 ° C , 0.01 mm Hg) Obtained pure product (9.44 g '%) as a colorless oil which solidified upon cooling below 1 ° C. *H NMR (CDC13): 5 2.0 (3H, d)5 2.1 (2H, m), 2.43(2H, t), 3.54(2H,t), 3.76(3H, s), 5.96(1H,q); E-isomer signal, 5 1·75(3Η,t) and 7· 05(1Η, q) 13C NMR (MeOH-d4): (5 14.4, 1 9.7, 32.5 1, 52.6, 1 30.1, 165.6, 177.4. Z:E ratio 29:1, determined by H1 NMR. C. 2 Preparation of methyl oxybutyrate 2-oxybutyric acid (15 g) was distilled under reduced pressure (84 ° C, 20 mm Hg) using a Kugelruhr apparatus to obtain 14 g of pure material. The 2-oxobutyric acid (14 g) was dissolved in methanol (anhydrous, 20 mL, 14 vol.), and dichloroethane (anhydrous, 80 mL, 5.7 vol) was taken in the presence of a few drops of ethanesulfonic acid. The reaction mixture was stirred at reflux under an inert atmosphere for 18 hours. It was then cooled, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude material was purified by distillation (b.p. 76 ° C, 20 mmH) to afford the product as a colorless oil (7.53 g, 48% yield). NMR (CDC13): <5 0.88 (3H, d), 2.66 (2H, q), 3.63 (3H, s) Reference biochemistry, 2670, 1 917. D. (Z)-2-(2-Oxotetrahydro-1Η-1-pyrrolyl)-2-butenoic acid methyl ester (Precursor-30- This paper scale applies to China National Standard (CNS) A4 specification ( 210 X 297 mm) (Please read the note on the back and fill out this page) Binding---------· Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed Clothing 1308912 A7 B7 29 V. Invention Description ( Preparation of A2). Packing (please read the precautions on the back and fill out this page). Feed the methyl 2-oxobutanoate in a 10 〇 ml flask equipped with a magnetic stir bar and a D-Stark valve. (7.5 g, 73 mmol), toluene (50 ml, 7 vol) and 2-pigebium hexanone (8.4 ml, 111 mmol, 1.5 eq.) followed by dropwise addition of hydrazine chloride (1.6 mL, 20) Millions, 0.2 7 equivalents). The reaction mixture was stirred under reflux with azeotropic distillation via a D-Stark valve to remove water for 8 hours. After cooling, the solution was washed with a 10% aqueous potassium hydrogensulfate solution (2 x 3 volume). The aqueous phase was saturated with sodium chloride and back extracted with toluene-6. The combined organic phases were dried over magnesium sulfate, filtered and concentrated in vacuo to afford crude material (7.5 g) as an orange oil. The crude oil was purified by distillation (92-94t, 0.1 mmH) to yield the product (4.7 g, 60%) as a colourless oil. Z:E ratio 6:1, determined by 1H NMR. Preparation of Ε·(Ε)-2-(2-oxytetrahydro-1Η-1-pyrrolyl)-2-butenoic acid methyl ester (precursor A2) Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed with Z-A1 (2 g, 11.8 mmol) of ethanol (2.2 ml, 37.3 mmol), tetrahydrofuran (THF, 40 ml, 20 volumes) and dimethylamine were fed into a 100 ml flask of a magnetic stir bar. Pyridine (DM AP, 150 mg ' 1.23 mmol), and the flask was placed under a nitrogen atmosphere. The reaction mixture was cooled to 0 °C before adding dicyclohexylmethyleneimine (DCC, 2.46 g, 11.9 mmol) and then heated to ambient temperature. The reaction mixture was stirred vigorously for 21 hours. Hexane (40 mL.) was then added to precipitate a solid. The precipitate was filtered off and the filtrate was concentrated in vacuo tolud. The oil was washed with water (40 ml) using dichloromethane (Dcm, 40 ml then 2 x 20 ml). The solvent was dehydrated by sodium sulfate and concentrated in vacuo to obtain 2 g of E-A2 B-31- This paper scale applies to the Chinese National Standard (CNS). A4 size (210 X 297 mm) 1308912 V. Description of the invention (3G) Ester (100% yield). F. Preparation of the drive A3: (z)-2-(2-oxytetrahydro-1H-1-pyrrolyl)-2-butenylamine (precursor A 3 ) 20 liter flanged bottle for erection Stir under an inert atmosphere and feed a :! (222 g '1.313 Moer' 1 equivalent) and anhydrous thf (7.0 L, 30 volumes). Any reaction mixture was cooled to below 5 ° C, and phosphorus pentachloride (300 g ' 1.44 mTorr'].1 equivalent) was added in portions, and the reaction temperature was maintained below that. The reaction mixture was stirred at -5 to 0 ° C for 1 hour and allowed to warm to 5 ° to dissolve the remaining phosphorus pentachloride ' and then cooled below 0 ° C. The sealed ice/acetone condenser was fitted to the flask. Ammonia (about 200 g) slowly passed through the solution to maintain the temperature below 15 °C. The suspension was stirred for a further 15 minutes and excess ammonia was removed by nitrogen for a few minutes. Methanol (3.7 L, 17 vol) was added and the reaction mixture was refluxed for 1-5 h then cooled to <RTI ID=0.0>> </RTI> <RTIgt; The filtrate was evaporated to give a yellow solid. This material was dissolved in methanol (640 mL, ca. 3 vol.) and ethyl acetate (440 mL, 2 vol.) and purified using anhydrous flash chromatography (EtOAc, EtOAc EtOAc EtOAc :1) Elution was carried out to obtain a crude product (288 g). The crude product was recrystallized from isopropanol (1.9 L, ca. 8.5 vol) to afford white crystals (127 g). The solid was dehydrated at ambient temperature in a vacuum oven to obtain A3 (1 18 g, 54%). 'H NMR (CDCb + several drops of MeOD): (5 6.75 ()H, q), 3.5 (2H, t), 2·5 (2Η, t), 2.15 (2H, m), 1·7 (3Η, d), trace impurities. Elemental analysis C 56.90 (57.1 3% theoretical 値); η 7.19 (7.19% theoretical 値); 1^ 1 6.3 2 (1 6.66% theoretical 値). -32- 1308912 V. Description of invention (32 The sirkan test tube was purged with hydrogen (5X vacuum/hydrogen) and stirred at ambient temperature for 1.5 hours. The clear red-orange solution was transferred via syringe to another sir Frank tube (using argon purge). The catalyst solution was under argon. Stored at ° C and used directly for hydrogenation (T etrahedr ο η, 1 2 4 5, 1 9 8 4) I. [RuhCl(R)-Binap (C6H6)] + Cl - was prepared with a magnetic stir bar and Anhydrous 200 ml of sulphur in an argon atmosphere was fed in a test tube [RuC12(C6H6)]2 (0.3 g, 0.66 mmol) and (R)-Binap (0.815 g, 1.3 mmol). Degassed anhydrous benzene (20 ml, 60 volumes) and ethanol (130 ml, 340 volumes), the solution was degassed (3x vacuum / argon). The reddish orange suspension was heated to 50-55 °C through 45 A clear brown solution was obtained in minutes. The solution was passed through celite. The pad was filtered under argon into another sir Frank tube. The solvent was evaporated in vacuo to give a yellow solid (1.08 g, 86%), which was stored at 0-5 ° C under argon. J, 3064, 1994) 〇J. [RuCl(R)-Binap(C6H6)] + BF4_ was prepared with a magnetic stir bar and fed in an anhydrous tube of 100 ml sulphur in an argon atmosphere [RuCl] (R)-Binap(C6H6)] + Cl- (0.45 g, 0.52 mmol) and degassed anhydrous dichloromethane (20 mL, 44 vol). The resulting solution was degassed (3x vacuum / argon) And transferred to another sir Frank tube containing a suspension of AgBF4 (0.15 g, 0.77 mmol, 1.5 eq.) in dichloromethane (] 〇 ml, 22 vol). The mixture was stirred vigorously. · 5 hours, then filtered through celite under argon atmosphere. The filtrate was concentrated in vacuo to give a green solid (0.42 g, 88%), which was stored at 0-5 ° C under argon (Journal of Organic Chemistry, 3064) ,] 994). -34- 1308912 Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printed A7 B7____ 33 ' ~ five, invention description () K-Ru (OCOCH3)2-[( The preparation of R)-BinaP] was equipped with a magnetic stir bar and fed in an anhydrous 200 ml sulphur tube under argon atmosphere [RuC12(C6H6)]2 (0.805 g, 1.60 mmol) and (R) _ Binap (1.89 g '3_03 Halo' 0.95 equivalent). Degassed anhydrous dimethylformamide (30 ml, 38 vol) was added and the solution was degassed (3 >< The reaction mixture was heated to 100 ° C for 10 minutes to obtain a dark red solution' and then cooled to ambient temperature. Sodium acetate (5.2 g, 63.4 mmol) was added to a reaction vessel and stirred for 5 minutes in methanol (50 mL, 60 vol.). Deaerated water (50 ml, 60 volumes) and toluene (25 ml '30 volumes) were added, and the reaction mixture was stirred vigorously for 5 minutes. The toluene layer was transferred via syringe to another sir Frank tube (using argon purge) and the aqueous phase was extracted with toluene (2 x 25 mL). The combined toluene solution was washed with water (4 χ 10 mL), and the solvent was concentrated in vacuo at 45 ° C and vacuum dried for 12 hours (0.1 mm Hg). The tan solid was dissolved in toluene (25 mL) without stirring and hexane (75 mL) was slowly added to afford a second layer. The two phase mixture was placed around for 7 hours and then placed at 0-5 ° C for 3 days. The catalyst crystallizes. The solvent was removed under a argon atmosphere by a syringe. The solid was washed with hexane (20 mL) and evaporated in vacuo for 2 hrs to give the catalyst as a tan solid (1.76 g, 70%). Tj ' 4053 , 1992) ° L. Asymmetric hydrogenation asymmetric hydrogenation of precursors A1, A2, A3 follows the same scheme for each precursor system. Therefore, only the asymmetric hydrogenation of A3 is described as follows. Asymmetric hydrogenation of precursor A3. -35- This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) (please read the notes on the back and fill out this page)
裝 · 1308912 A7 _______B7____ 3 5五、發明說明(') 水相經蒸發獲得淡黃色固體(4.83克,80%)。固體(4克)溶 解於丙酮(24毫升,6容積),及回流加熱1小時。溶液以 5-lOt/小時速率緩慢冷卻至〇°C。晶體經過濾出,使用丙 酮(1.6毫升,0.4容積)洗滌及脫水獲得白色固體(3.23克 ,8 1 % > > 9 9 · 8 % e. e.,5 4 p p m R h)。 (S)-a -乙基-2-氧基-1-吡咯啶乙醯胺(左堤拉西坦)之純化: 經由前述非對稱氫化所得左堤拉西坦(5克,9 8 % e. e.)由 丙酮(30毫升,6容積)如前述再結晶獲得白色結晶固體 (3.94 克,81%,>99.8%e.e.,52ppm Rh)。此物料(3 克)再 度如前述再結晶獲得白色結晶固體(2.31克,77%, >99.80/〇e.e.,23ppm Rh)。 熔點 118.4-119.9°C。 (請先閱讀背面之注意事項再填寫本頁) i—裝 ^1 .^1 ^1-,· n I . f 經濟部智慧財產局員工消費合作社印製 -37- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公f ) 1308912 ;98, 2. 0 2装 · 1308912 A7 _______B7____ 3 5 V. Description of the invention (') The aqueous phase was evaporated to give a pale yellow solid (4.83 g, 80%). The solid (4 g) was dissolved in acetone (24 mL, 6 vol.) and heated at reflux for one hour. The solution was slowly cooled to 〇 ° C at a rate of 5-lOt / hour. The crystals were filtered, washed with acetone (1.6 mL, 0.4 vol.) and dried to give a white solid (3.23 g, 81% >> 9 9 · 8 % e. e., 5 4 p p m R h). Purification of (S)-a-ethyl-2-oxy-1-pyrrolidineacetamide (Littiracetam): Levetiracetam obtained by the aforementioned asymmetric hydrogenation (5 g, 9 8 % ee A white crystalline solid (3.94 g, 81%, > 99.8% ee, 52 ppm Rh) was obtained from acetone (30 ml, 6 vol.). This material (3 g) was recrystallized as above to give a white crystalline solid (2.31 g, 77%, >99.80 / 〇e.e., 23 ppm Rh). Melting point 118.4-119.9 ° C. (Please read the notes on the back and fill in this page) i—Installation ^1 .^1 ^1-,· n I . f Ministry of Economic Affairs Intellectual Property Bureau Employees Consumption Cooperative Printed -37- This paper scale applies to Chinese national standards (CNS) A4 specification (210 X 297 public f ) 1308912 ;98, 2. 0 2
FP11556C 申請曰期 案 號 類 別 口 A4|女4丨 羃遭專利説明書(2Q_2月修正} 發明 —、新型名稱 中 文 2-氧基-1-吡咯啶衍生物之製法 英 文 PROCESS FOR PREPARING 2-OXO-1-PYRROLIDINE 1 DERIVATIVES 姓.名 國 發明 創作> 1·約翰蘇帝斯(JOHN SURTEES) 2. 維爾利特瑪孟(VIOLETA MARMON) 3. 艾德蒙迪弗丁 (EDMOND DIFFERDING) 4 ·文生齊麥曼(VINCENT ZIMMERMANN)1.英國2.保加利亞3.盧森堡4.比利時 裝 住、居所 1. 比利時瓦特梅爾珀茲福特B-1170克勞斯迪斯宣尼斯52號2. 英國0X14 1XZ牛津郡亞平頓蓋斯比路26號3_比利時歐梯格尼斯-勞凡-拉-紐威B-1348布婁克雷路55號 4.瑞士洛桑拉康維辛CH-1093康維尼路87號 訂FP11556C Application for the case number category A4|female 4丨羃 patent specification (2Q_2 month amendment} Invention-, new name Chinese 2-oxy-1-pyrrolidine derivative method English PROCESS FOR PREPARING 2-OXO- 1-PYRROLIDINE 1 DERIVATIVES Last name. Famous country invention &creation; 1. John SURTEES 2. VIOLETA MARMON 3. EDMOND DIFFERDING 4 · Wensheng Qi VINCENT ZIMMERMANN 1.UK 2.Bulgaria 3.Luxembourg 4.Belgian accommodation, residence 1. W. Merced Pittsburgh, Belgium B-1170 Klaus Diss, 52. 2. UK 0X14 1XZ Oxfordshire No. 26, Gaither Road, Upington, Belgium 3_ Belgium Otignis-Laofen-La-Norwey B-1348 Buchenkele Road No. 55 4. Switzerland, Lausanne, Convisin CH-1093, Conviny Road, 87
優稀美法契姆股份有限公司 UCB Farchim SA 經濟部智慧財產局員工消費合作社印製 線 瑞士 瑞士布爾CH-1630 C.P.411赤密第克羅伊艾克斯-白浪希 10號Z.I.普拉奇 罕立特凡康尼根(Henriette Van Caenegem) 本紙張尺度適用中國國家檩率(CNS〉A4规格(210 X297公嫠 1308912 A7 B7 年f月^!修(^)王替換頁 14 五、發明說明() 具體實施例,本發明係有關一種製備式(B)化合物之方法Ubi Fachim SA UCB Farchim SA Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printing Line Switzerland Switzerland Boer CH-1630 CP411 Chimi Di Croix Aix - Bailangxi No. 10 ZI Plachihan Henriette Van Caenegem This paper scale applies to China's national rate (CNS>A4 specification (210 X297 嫠1308912 A7 B7 year f month^!修(^)王换页14 V. Invention description ( DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a process for the preparation of a compound of formula (B)
其中R1、R2、R3、R4及X定義如前,該方法係經由如前 舉例說明且定義如前之對應式(A)化合物之催化非對稱性 氫化反應獲得。催化氫化說明於多種公開文獻或書籍例如 「催化非對稱合成·輔助之.對掌配體」】3〇91^1丨1^867(1611-Penne( 1 994)-Savoirs actuel, interEdition/CNRS Edition-7.1 章「氫化催化劑」287-300頁。 除非另行陳述,否則於此處述及通式(B)化合物無論個 別或集合皆意圖包括幾何異構物,亦即Z(住沙門)及E(安 久占)異構物,以及對映異構物、非對映異構物及各 '別混 合物(外消旋混合物)。 較佳本發明方法係有關製備式(B)化合物,其中R2及R4 爲氫及X爲-COOH或-COOMe或-COOEt或-CONH2,以及 R1爲甲基;特別其中R3爲氫、烷基(特別丙基)或鹵烯基 (特別二氟乙烯基)。使用左堤拉西坦之製法獲得最佳結果 ,式(B)化合物其中R1爲甲基,R2及R4爲氫,R3爲氫、 丙基或二氟乙烯基,及X爲-conh2。 通常此種方法包括前將述式(A)化合物進行催化氫化反 應。較佳式(A)化合物係使用基於铑(Rh)或釕(Ru)蟄合劑之 對掌催化進行非對稱氫化。非對稱氫化方法述於許多公開 -16- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) --------tT----------0 經濟部智慧財產局員工湞費合作社印製 1308912 =替換頁 ^ 15、 五、發明說明() 文獻或書籍例如「非對稱合成」R.A. Aitken以及S.N. Kilenyi(l 992)-布來奇(Blackie)學術及專業出版或「光學活 性胺基酸之合成」Robert Μ· willimas(1 989)-波加蒙出版 社。 對掌螫合配體之Rh(I)及Ru(II)複合體通常爲二膦類用於 烯烴的非對稱氫化極爲成功。許多對掌二螫合基配體例如二亞 膦酸鹽、貳(胺基膦)及胺基膦亞膦酸鹽或對掌催化劑錯合物述 於參考文獻且爲市面可得。對掌催化劑也可結合相對離子及/ 或烯烴。 雖然已經累積許多對掌催化劑之催化活性及立體選擇性之資 訊,但對個別基質而言,配體、對掌催化劑及反應條件的選擇 仍然係靠實驗進行。通常以Rh( I )爲主的系統大半用於製備胺 基酸衍生物,Ru(n)催化劑對寬廣烯屬基質可獲得絕佳結果。 用於本發明之對掌催化劑螫合劑有杜弗斯(DUPHOS ),BPPM, BICP ’ BINAP , DIPAMP , SKEWPHOS , BPPEA , DIOP , NORPHOS , PROPHOS,PENNPHOS,QUPHOS,BPPMC,BPPFA。 由前述螫合劑製備的經支載或以其它方式制動催化劑也可用 於本發明,俾除了改良催化劑的回收以及循環利用之外也獲 得改良轉換率或選擇性。較佳用於本發明方法之.對掌催化劑螫 合劑係選自杜弗斯或甲基、二乙基、二異丙基-杜弗斯(1,2-貳 2,5-二甲基磷諾基(phospholano))苯-美國專利第5,171,892 號)’ DIPAMP(膦’ 1,2-乙二基貳((2-甲氧苯基)苯基-美國 專利第4,008,28 1及4,1 42,992號),BPPM(1-吡咯啶羧酸 -17- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) n — » n ·1 >1 n n 1 . 經濟部智慧財產局員工消費合作社印制衣Wherein R1, R2, R3, R4 and X are as defined above, the process is obtained via a catalytic asymmetric hydrogenation reaction as exemplified above and defining a compound of formula (A) as before. Catalytic hydrogenation is described in various publications or books such as "catalytic asymmetric synthesis and auxiliary. Pair of ligands" 3〇91^1丨1^867(1611-Penne(1 994)-Savoirs actuel, interEdition/CNRS Edition -7.1 "Hydrogenation Catalysts", pp. 287-300. Unless otherwise stated, the compounds of formula (B) described herein are intended to include geometric isomers, ie, Z (Salmon) and E (individually or collectively). Isomers, as well as enantiomers, diastereomers and individual mixtures (racemic mixtures). Preferably, the process of the invention relates to the preparation of compounds of formula (B) wherein R2 and R4 Is hydrogen and X is -COOH or -COOMe or -COOEt or -CONH2, and R1 is methyl; in particular wherein R3 is hydrogen, alkyl (special propyl) or haloalkenyl (particularly difluorovinyl). The best results are obtained by the method of dirasacetam wherein R1 is methyl, R2 and R4 are hydrogen, R3 is hydrogen, propyl or difluorovinyl, and X is -conh2. Including the catalytic hydrogenation reaction of the compound of the above formula (A). The preferred compound of the formula (A) is based on rhodium (Rh). Or asymmetric hydrogenation of the ruthenium (Ru) chelating agent. The asymmetric hydrogenation method is described in many publications-16- This paper scale applies to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) (please read first) Note on the back side of this page) --------tT----------0 Ministry of Economic Affairs Intellectual Property Bureau employee fee cooperative cooperative printing 1308912 = replacement page ^ 15, five, invention Description () Documents or books such as "Asymmetric Synthesis" RA Aitken and SN Kilenyi (l 992) - Blackie Academic and Professional Publications or "Synthesis of Optically Active Amino Acids" Robert Μ· willimas (1 989) - Bocamon Press. The Rh(I) and Ru(II) complexes of the ruthenium ligands are generally diphosphines for the asymmetric hydrogenation of olefins. Many pairs of ruthenium ligands such as Diphosphinates, hydrazines (aminophosphines) and amine phosphine phosphinates or palm catalyst conjugates are described in the literature and are commercially available. The catalysts can also be combined with counterions and/or olefins. Although many information has been accumulated on the catalytic activity and stereoselectivity of the catalyst, for individual groups In general, the choice of ligands, catalysts and reaction conditions is still experimental. Typically, Rh(I)-based systems are mostly used to prepare amino acid derivatives, and Ru(n) catalysts for broad olefinic substrates. Excellent results are obtained. The catalyst chelating agents used in the present invention are DUPHOS, BPPM, BICP 'BINAP, DIPAMP, SKEWPHOS, BPPEA, DIOP, NORPHOS, PROPHOS, PENNPHOS, QUPHOS, BPPMC, BPPFA. Supported or otherwise braked catalysts prepared from the foregoing chelating agents can also be used in the present invention to achieve improved conversion rates or selectivities in addition to improved catalyst recovery and recycling. Preferably used in the method of the invention. The catalyst chelating agent is selected from the group consisting of Dufus or methyl, diethyl, diisopropyl-dufus (1,2-贰2,5-dimethylphosphine). Phosphono) benzene - U.S. Patent No. 5,171,892) 'DIPAMP (phosphine' 1,2-ethanediyl fluorene ((2-methoxyphenyl)phenyl) - US Patent No. 4,008,28 1 and 4 , No. 1, 42,992), BPPM (1-pyrrolidine carboxylic acid-17- This paper size applies to China National Standard (CNS) A4 specification (210 X 297 mm) (please read the notes on the back and fill out this page) n — » n ·1 >1 nn 1 . Ministry of Economic Affairs Intellectual Property Office Staff Consumer Cooperative Printed Clothing
替換I 經濟部智慧財產局員工消費合作社印製 1308912 心 16 五、發明說明() ,4-(二苯基膦基)-2-((二苯基膦基)甲基)-1,1-二甲基乙基 酯-日本專利第8704523 8號)及BIN AP (膦,(1,1’-聯萘)-2,2’-二基貳(二苯基-歐洲專利案第〇 366 390號)。 此等螫合劑之結構式顯示如下。Replacement I Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed 1308912 Heart 16 V. Invention Note (), 4-(Diphenylphosphino)-2-((diphenylphosphino)methyl)-1,1- Dimethylethyl ester - Japanese Patent No. 8704523 8) and BIN AP (phosphine, (1,1'-binaphthyl)-2,2'-diylindole (diphenyl-European Patent No. 366 390 No.) The structural formula of these chelating agents is shown below.
(R)-BINAP 較佳用於本發明方法之溶劑係選自四氫呋喃(THF),二 甲基甲醯胺(DMF),乙醇,甲醇,二氯甲烷(DCM),異丙 醇(IPA),甲苯,乙酸乙酯(AcOEt)。 相對離子係選自鹵陰離子(鹵(-)),BPh4(-)CI04(-), BF4(-),PF6(-),PC16(-),OAc(-),三氟甲烷磺酸基(〇Τ£(-)) ’甲烷磺酸基或甲烷磺酸酯。較佳用於對掌催化劑之相對離子 係运自 OTf(-)、BF4(-)或 OAc(-)。 烯烴係選自乙烯,1,3-丁二烯,苯,環己二烯,原冰片 -18- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -n n ί I n n n n n n 0 I n n n n a^i __ , it 1 I n I n l I (請先閱讀背面之注意事項再填寫本頁)(R)-BINAP The solvent preferred for use in the process of the invention is selected from the group consisting of tetrahydrofuran (THF), dimethylformamide (DMF), ethanol, methanol, dichloromethane (DCM), isopropanol (IPA), Toluene, ethyl acetate (AcOEt). The relative ion system is selected from the group consisting of halogen anions (halogen (-)), BPh4(-)CI04(-), BF4(-), PF6(-), PC16(-), OAc(-), trifluoromethanesulfonate ( 〇Τ£(-)) 'Methanesulfonate or methane sulfonate. Preferably, the relative ion system for the palm catalyst is transported from OTf(-), BF4(-) or OAc(-). The olefin is selected from the group consisting of ethylene, 1,3-butadiene, benzene, cyclohexadiene, and raw borneol-18-. The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) -nn ί I nnnnnn 0 I nnnna^i __ , it 1 I n I nl I (Please read the note on the back and fill out this page)
經濟部智慧財產局員工消費合作社印制^ Ϊ308912 五、發明說明() 二烯或環辛-1,5-二烯(COD)。 使用此等對掌催化劑組合一定範圍之相對離子且催化 劑-基質比係於1:20至1:20,000之範圍於商用溶劑之範圍 內,可將式(A)化合物轉成具有高度百分比對映異構物過 量(e.e.)以及絕佳產率及高純度之式(B)化合物之左旋或右 旋對映異構物。此外,此種辦法係使用標準產業工廠及設 備,因此具有成本上的優勢。 此種非對稱合成方法由於可避免習知合成方法所得非期 望對映異構物之回收或拋棄問題,故也可降低成本。 使用製備(S)-a ·乙基-2-氧基-1-吡咯啶乙醯胺或(R)- a -乙基-2-氧基-1-吡咯啶乙醯胺之方法可獲得最佳結果,其 中包含呈Z異構物或E異構物形式之式A’化合物根據如 下反應圖使用對掌催化劑接受非對稱氫化反應。Printed by the Ministry of Economic Affairs, Intellectual Property Bureau, Staff Consumer Cooperatives ^ Ϊ 308912 V. Invention Description () Diene or cyclooctane-1,5-diene (COD). The compounds of formula (A) can be converted to a high percentage enantiomer using a combination of such a pair of catalysts to a range of relative ions and a catalyst-matrix ratio ranging from 1:20 to 1:20,000 in the range of commercial solvents. An excess of the structure (ee) and a left-handed or right-handed enantiomer of the compound of formula (B) in excellent yield and high purity. In addition, this approach uses standard industry plants and equipment and therefore has a cost advantage. Such asymmetric synthesis methods can also reduce costs by avoiding the problem of recovery or disposal of the undesired enantiomers obtained by conventional synthetic methods. The most preferred method is to prepare (S)-a-ethyl-2-oxy-1-pyrrolidinium or (R)-a-ethyl-2-oxy-1-pyrrolidinium. The result, which comprises a compound of formula A' in the form of a Z isomer or an E isomer, is subjected to an asymmetric hydrogenation reaction using a palm catalyst according to the following reaction scheme.
後文將特別參照四種式(A)化合物說明,其中Ri爲甲基 、R2、R3及R4爲氫,以及 對後文標示爲前驅物A1之化合物而言,X爲-CO〇H ; 對後文標示爲前驅物A2之化合物而言,X爲_C00Me ; 對後文標示爲前驅物A2’之化合物而言,X爲_C00Et ; 以及 對後文標示爲前驅物A3之化合物而言,X爲_C0NH2。 -19- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)~ (請先閱讀背面之注意事項再填寫本頁)Reference will now be made in detail to the four compounds of formula (A) wherein Ri is methyl, R2, R3 and R4 are hydrogen, and for compounds which are hereinafter referred to as precursor A1, X is -CO〇H; In the case of the compound labeled as precursor A2, X is _C00Me; for the compound labeled as precursor A2', X is _C00Et; and for the compound labeled as precursor A3, X is _C0NH2. -19- This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm)~ (Please read the note on the back and fill out this page)
13089121308912
(#正替換頁 五、發明説明(2ι) 實例4 前驅物A3之合成可經由烯醯胺酸與五氯化磷反應獲得 酶氯’及然後與氣態氨反應獲得預定烯醯胺醯胺A3進行 產物證實爲Z-異構物。 粗烯醯胺醯胺A3係經由於THF-MeOH蒸餾,及過濾去 除無機殘餘物而由反應混合物中分離。蒸發去除溶劑後, 獲得黃色固體。粗料係藉無水急速層析純化,接著由異丙 醇再結晶獲得純物料。此種程序可成功地應用於製造單批 A3(l 18克,54%,>99%尖峰面積)且摘述於反應圖12。(#正换页页五,发明说明(2ι) Example 4 Synthesis of precursor A3 can be carried out by reacting linoleic acid with phosphorus pentachloride to obtain enzyme chlorine' and then reacting with gaseous ammonia to obtain a predetermined olefin amidoxime A3. The product was confirmed to be a Z-isomer. The crude olefin amidoxime A3 was isolated from the reaction mixture by distillation in THF-MeOH and filtered to remove inorganic residue. After evaporation of solvent, a yellow solid was obtained. Purification by anhydrous flash chromatography followed by recrystallization from isopropanol to obtain a pure material. This procedure was successfully applied to the manufacture of a single batch of A3 (18 g, 54%, > 99% peak area) and is summarized in the reaction scheme. 12.
前驅物A3Precursor A3
OHOH
1. PCl5,THF,:2O;0M,(n 2· NH;氣體 3. 無水急速,Si〇2-llwt 4. 再結晶·異丙醇~ 前驅物A 1 Μ%鈕產率 反應圖12 大部分前驅物之非對稱氫化反應中,前驅物係經由 [Rh(CDO)2] + 〇Tr與個別對掌配體於首選溶劑反應,接著 加入基質而原位製備。若干催化劑爲市面可得,且未經進 一步純化即供使用。 實例5 使用多種以錢爲主的催化劑系統對前驅物A 1及A 2進 行非對稱氫化所得結果摘述於下表1。反應係使用0.00 5 莫耳%至5莫耳%催化劑以及100毫克或200毫克基質於 周圍溫度(室溫)進行24小時。反應條件如氫壓、溶劑種類 、前驅物量經修改俾獲得最理想條件。全部產物係由反應 -23-1. PCl5, THF,: 2O; 0M, (n 2 · NH; gas 3. anhydrous rapid, Si〇2-llwt 4. recrystallization · isopropanol ~ precursor A 1 Μ% button yield reaction Figure 12 In the asymmetric hydrogenation of a portion of the precursor, the precursor is prepared in situ by reacting [Rh(CDO)2] + 〇Tr with the individual palm ligands in the preferred solvent, followed by the addition of the matrix. Several catalysts are commercially available, And used without further purification.Example 5 The results of asymmetric hydrogenation of precursors A 1 and A 2 using a variety of money-based catalyst systems are summarized in Table 1 below. The reaction system uses 0.00 5 mol% to 5 mol% catalyst and 100 mg or 200 mg substrate were subjected to ambient temperature (room temperature) for 24 hours. The reaction conditions such as hydrogen pressure, solvent type, and precursor amount were modified to obtain the most ideal conditions. All products were reacted by -23-
1308912 τ- 22 ι、發明說明() 混合物中蒸發去除溶劑分離,且未經進一步純化藉ιΗ-NMR光譜術分析。 HPLC(高效液相層析術)方法用於前驅物A 1氫化產物之 %e.e.測定。因此,發明人使用重氮甲烷於THF溶液將粗 產物轉成甲酯。然後酯衍生物使用對掌HPLC方法分析監 視烯醯胺酯A2之氫化反應。用於HPLC方法,發明人使 用對掌外徑4.6x25 0毫米管柱及異丙醇/正己烷(95:05)作 爲溶析液。 對前驅物A2之氫化產物,經由下述對掌HPLC方法獲 得e.e.結果:開洛塞(Chiralcel)外徑4.6x250毫米,異丙 醇-己烷(5:95ν/ν),2Θ5毫微米,1毫升/分鐘於周圍溫度(rt) ,樣本1毫克/毫升,13分鐘(S-對映異構物),16分鐘(R-對映異構物)。最初,篩選係於100毫克規模使用5莫耳% 催化劑進行。 對映異構物過量(e.e.)百分比結果爲正表示左旋S-對映 異構物百分比,以及負表示右旋R-對映異構物百分比。 (請先閱讀背面之注音?事項再填寫本頁) 襄--------訂--------- 翁. 經濟部智慧財產局員工消費合作杜印製 -24- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1308912 A7 B7 月7Vi: @讀换頁 25 五、發明說明() 表中Cou.表示相對離子;Loa.表示載荷莫耳% ; H2 Pres. 表示氫壓;以及rt表示室溫。 如前述,铑催化劑已經於原位製備或購買且未經進一步 純化即供使用。钌催化劑係根據已知參考文獻程序製備。 大部分實驗係於100毫克至15毫克規模使用0.001莫耳% 至5莫耳%催化劑進行。粗產物係藉iH,13C-NMR光譜術 分析,以及藉對掌HPLC分析。1308912 τ- 22 ι, description of the invention () The solvent was removed by evaporation in the mixture and was analyzed by EtOAc-NMR spectrum without further purification. The HPLC (High Performance Liquid Chromatography) method was used for the %e.e. determination of the hydrogenated product of the precursor A1. Therefore, the inventors converted the crude product to a methyl ester using diazomethane in a THF solution. The ester derivative is then used to analyze the hydrogenation of the olefinic amine ester A2 using a HPLC method. For the HPLC method, the inventors used a 4.6 x 25 mm column for the outer diameter of the palm and isopropanol/n-hexane (95:05) as the eluent. For the hydrogenated product of precursor A2, the ee results were obtained by the following HPLC method: Chiralcel outer diameter 4.6 x 250 mm, isopropanol-hexane (5:95 v/v), 2 Θ 5 nm, 1 ML/min at ambient temperature (rt), sample 1 mg/ml, 13 min (S-enantiomer), 16 min (R-enantiomer). Initially, the screening was carried out using a 5 mol% catalyst on a 100 mg scale. The percentage of enantiomeric excess (e.e.) is positive for the percentage of L-S enantiomers and negative for the % R-enantiomer. (Please read the phonetic transcription on the back? Please fill out this page again) 襄--------Book--------- Weng. Ministry of Economic Affairs Intellectual Property Bureau employee cooperation cooperation Du printing system 24-- Ben Paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 1308912 A7 B7 Month 7Vi: @读换页 25 V. Invention description () Cou. indicates relative ion; Loa. indicates load mol% ; H2 Pres. means hydrogen pressure; and rt means room temperature. As described above, the rhodium catalyst has been prepared or purchased in situ and used without further purification. Ruthenium catalysts were prepared according to known reference procedures. Most of the experiments were carried out using a catalyst ranging from 0.001 mol% to 5 mol% on a 100 mg to 15 mg scale. The crude product was analyzed by iH, 13 C-NMR spectroscopy, and analyzed by HPLC.
100- 500 mg (請先閱讀背面之注意事項再填寫本頁) 反應圖1 3 *製造相反對映異構物。 實例7 :使用Rh-(Et,Et)-杜弗斯非對稱氫化前驅物A3 A3使用Rh-杜弗斯催化劑氫化結果示於表3。此等反應 係以如實例5及6之相同方式使用氫壓4大氣壓進行。 經濟部智慧財產局員工消費合作杜印製 通常,Rh-杜弗斯催化α -醢基胺基丙烯酸衍生物之氫化 反應之對映選擇性顯示極小溶劑效應。但仍然無法事先預 測對應選擇性的影響,以及對指定基質反應速率的影響。 觀察A3之氫化反應與溶劑有高度關聯。發現非配位質子 惰性溶劑DCM優異。於質子醇系溶劑氫化導致反應較緩 慢且選擇性降低。同理,於極性質子惰性溶劑如乙酸乙酯 及THF觀察得轉化率減低,二者預期皆與金屬配位且可 -27- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A7 B7100- 500 mg (Please read the notes on the back and fill out this page) Reaction Figure 1 3 * Manufacture of the opposite enantiomer. Example 7: Hydrogenation results using a Rh-(Et, Et)-Doufs asymmetric hydrogenation precursor A3 A3 using a Rh-Dufs catalyst are shown in Table 3. These reactions were carried out in the same manner as in Examples 5 and 6 using a hydrogen pressure of 4 atm. Ministry of Economic Affairs, Intellectual Property Office, Staff Consumption Cooperative Printing, Generally, the enantioselectivity of the hydrogenation reaction of Rh-Doffers catalyzed α-mercapto-acrylic acid derivatives shows a minimal solvent effect. However, it is still not possible to predict in advance the effect of the selectivity and the effect on the rate of reaction of the specified substrate. It is observed that the hydrogenation reaction of A3 is highly correlated with the solvent. The non-coordinating protic solvent DCM was found to be excellent. Hydrogenation of the protic alcohol solvent results in a slower reaction and a lower selectivity. Similarly, the conversion is observed in a polar aprotic solvent such as ethyl acetate and THF. Both are expected to be coordinated with the metal and can be used in the Chinese National Standard (CNS) A4 specification (210 X 297). Mm) A7 B7
1308912 五、發明說明(31) A3(l 08克)再度由異丙醇(1升,9.3容積)再結晶獲得最 後批料用於氫化硏究(100克,93%) ° 熔點 172.0°C -174.2°C。 元素分析(%m/m): C 56.95(57.1 3%理論値);Η 7.10 (7.19%理論値);Ν 1 6.38(1 6.66%理論値)。 TLC:Si02,甲苯 / AcOH/MeOH(4:l :0.5),UV 及茴香醛染 色。 G. 像合铑及釕催化劑之製備-[Rh(I)L*COD] + OTr(0.15M溶 液)之製備 [Rh(I)L*COD2] + OTr(35毫克,0.075毫莫耳)以及對掌 配體(L*,0.. 83毫莫耳,1.1當量)快速於空氣中稱重以及 進給至燒瓶。燒瓶使用橡皮隔膜密封以及以氬氣掃除。無 水且經過除氣的溶劑(5毫升,143容積)經隔膜添加。反應 混合物經除氣(3x真空/氬氣)及攪拌30分鐘或至全部固體 溶解爲止。 H. Rh(I)(MeOH)2[(R)-Binap]之製備 配備有磁攪棒之無水200毫升西蘭克(Schlenk)試管內進 給[Rh(I)(nbd)2]C104(251 毫克,0.649 毫莫耳)及(R)-Binap (4〇5毫克,0.6 5毫莫耳)且置於氬氣氣氛下。二氯甲烷(無 水,除氣,5毫升’ 20容積)經注射器添加且反應混合物 經除氣(3x真空/氬氣)。緩慢加入四氫呋喃(無水,除氣, 1 0毫升,4〇容積)接著加入己烷(無水,除氣,2〇毫升, 8〇容積)。所得懸浮液於0-51維持1 6小時。於氬下傾析 去除溶劑’及加入甲醇(無水,除氣,5毫升,20容積)。 -33- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) T. -n -I— n n n ^ ^ · n If n n i^i n I I - i 經濟部智慧財產局員工消費合作社印制取1308912 V. INSTRUCTIONS (31) A3 (10 gram) is recrystallized from isopropanol (1 liter, 9.3 vol) to obtain the final batch for hydrogenation (100 g, 93%) ° melting point 172.0 ° C - 174.2 ° C. Elemental analysis (%m/m): C 56.95 (57.1 3% theoretical 値); Η 7.10 (7.19% theoretical 値); Ν 1 6.38 (1 6.66% theoretical 値). TLC: SiO 2 , toluene / AcOH / MeOH (4: 1 : 0.5), UV and anisaldehyde dyed. G. Preparation of combined ruthenium and ruthenium catalysts - Preparation of [Rh(I)L*COD] + OTr (0.15M solution) [Rh(I)L*COD2] + OTr (35 mg, 0.075 mmol) and The palm ligand (L*, 0.. 83 mmol, 1.1 equivalent) was quickly weighed in air and fed to the flask. The flask was sealed with a rubber diaphragm and purged with argon. A water-free and degassed solvent (5 mL, 143 vol) was added via a septum. The reaction mixture was degassed (3x vacuum / argon) and stirred for 30 minutes or until all solids were dissolved. Preparation of H. Rh(I)(MeOH)2[(R)-Binap] Anhydrous 200 ml of Schlenk in vitro fed with a magnetic stir bar [Rh(I)(nbd)2]C104 ( 251 mg, 0.649 mmol, and (R)-Binap (4〇5 mg, 0.6 5 mmol) and placed under an argon atmosphere. Dichloromethane (no water, degassing, 5 ml '20 vol) was added via syringe and the reaction mixture was degassed (3x vacuum / argon). Tetrahydrofuran (anhydrous, degassing, 10 mL, 4 Torr volume) was added slowly followed by hexane (anhydrous, degassing, 2 mL, 8 〇 volume). The resulting suspension was maintained at 0-51 for 16 hours. The solvent was removed by decantation under argon and methanol (anhydrous, degassing, 5 ml, 20 volumes) was added. -33- This paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) (please read the notes on the back and fill out this page) T. -n -I- nnn ^ ^ · n If nni^ In II - i Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed
替換頁 1308912 五、發明説明(34) 於大氣壓氫氣壓力下氫化 配備有磁攪棒之無水1 0 0毫升西蘭克試管內進給基質 (5 00毫克,3毫莫耳)且以氬氣掃除。經注射器加入經除氣 的溶劑,接著加入催化劑溶液(〇.5至2.5莫耳%)。反應混 合物經除氣(3x真空/氬氣),然後使用氫氣汽球以氫氣掃 除(5x真空/氫)。反應於周圍溫度攪拌16-65小時。氫氬 氣氛與氮氣交換,真空蒸發去除溶劑獲得粗產物,粗產物 藉NMR光譜分析及對掌HPLC分析分析。 於4大氣壓壓力下進行氫化 全部操作皆係於氣氛帶(众加05:83§)(亞利希(六1(11^}1)化 學公司)於氬氣氣氛下下進行。基質(500- 1 000毫克)置於不 鏽鋼高壓容器(法國文希(Vince)技術公司),高壓容器嵌合 鐵弗龍嘴(或玻璃皿)以及鐵弗龍塗層磁攪棒。經除氣的溶 劑及催化劑或催化劑溶液(0.25至2.5莫耳%)加入其中。 容器經密封,及藉加壓容器至4.5-5.5大氣壓而以氫氣掃 除,然後解除加壓(5次)。最後,壓力調整至預定程度, 反應混合物周圍溫度攪拌1 6-65小時。完成時,氫壓與氮 氣交換,溶劑經真發去除獲得粗產物,粗產物藉NMR光 譜分析及像合Η P L C分析分析。 終物料之純化:(S)- ct -乙基-2-氧基-;1 -吡咯啶乙醯胺(左堤 拉西坦)之純化 藉前述非對稱氫化所得左堤拉西坦(5克,9 8 % e. e.)溶解 於水(20毫升,4容積)及使用乙酸乙酯(3 X〗0毫升,3 x2 容積)萃取,然後有機相以水(10毫升,2容積)回萃取,及 -36-Replacement page 1308912 V. INSTRUCTIONS (34) Hydrogenated 1000 ml irlancoin in-feed matrix (500 mg, 3 mmol) equipped with a magnetic stir bar under atmospheric pressure of hydrogen and purged with argon . The degassed solvent was added via a syringe followed by a catalyst solution (〇.5 to 2.5 mol%). The reaction mixture was degassed (3x vacuum/argon) and then purged with hydrogen (5x vacuum/hydrogen) using a hydrogen balloon. The reaction was stirred at ambient temperature for 16-65 hours. The atmosphere of hydrogen argon was exchanged with nitrogen, and the solvent was removed by evaporation in vacuo to give a crude material. The crude product was analyzed by NMR spectral analysis and HPLC analysis. The hydrogenation at 4 atm pressure was carried out in an atmosphere zone (Zhongjia 05:83 §) (Arlich (6 1 (11^11) Chemical Company) under an argon atmosphere. Substrate (500- 1 000 mg) placed in a stainless steel high pressure vessel (Vince Technologies, France), a high pressure vessel fitted Teflon mouth (or glass dish) and a Teflon coated magnetic stir bar. Degassed solvent and catalyst Or a catalyst solution (0.25 to 2.5 mol%) is added thereto. The container is sealed, and is purged with hydrogen by a pressurized container to 4.5-5.5 atm, and then depressurized (5 times). Finally, the pressure is adjusted to a predetermined level. The temperature of the reaction mixture is stirred for 16-65 hours. Upon completion, the hydrogen pressure is exchanged with nitrogen, and the solvent is removed by real hair to obtain a crude product. The crude product is analyzed by NMR spectroscopy and analyzed by PLC. The final material is purified: (S Purification of ct-ethyl-2-oxo-l-pyrrolidineacetamide (left ferracetam) by the aforementioned asymmetric hydrogenation of levetiracetam (5 g, 98% ee) In water (20 ml, 4 volumes) and using ethyl acetate (3 X 〗 0 ml , 3 x 2 volume) extraction, then the organic phase is extracted back with water (10 ml, 2 volumes), and -36-
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW90107984A TWI308912B (en) | 2001-04-03 | 2001-04-03 | Process for preparing 2-oxo-1-pyrrolidine derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW90107984A TWI308912B (en) | 2001-04-03 | 2001-04-03 | Process for preparing 2-oxo-1-pyrrolidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI308912B true TWI308912B (en) | 2009-04-21 |
Family
ID=45071928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW90107984A TWI308912B (en) | 2001-04-03 | 2001-04-03 | Process for preparing 2-oxo-1-pyrrolidine derivatives |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI308912B (en) |
-
2001
- 2001-04-03 TW TW90107984A patent/TWI308912B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2355680C2 (en) | 2-oxo-1-pyrrolidine derivatives, method of obtainment | |
| JP2002507222A (en) | Method for producing substituted perhydroisoindole | |
| JP4426012B2 (en) | Process for the enantioselective hydrogenation of homogeneous ester and acid compounds and use of hydrogenation products | |
| Cabrera et al. | Homochiral l-prolinamido-sulfonamides and their use as organocatalysts in aldol reactions | |
| TWI308912B (en) | Process for preparing 2-oxo-1-pyrrolidine derivatives | |
| MXPA01002945A (en) | Process for the preparation of ethanesulfonyl-piperidine derivatives. | |
| TW200536828A (en) | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | |
| JP4904517B2 (en) | Method for producing racemic piperidine derivatives | |
| HK1070659A (en) | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | |
| HK1084668A (en) | 2-oxo-1-pyrrolidine derivative and its pharmaceutical uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |